PCV64 - THE DIRECT RESOURCE USE AND MEDICAL COSTS OF HEART FAILURE IN NOVA SCOTIA, CANADA (English)
- New search for: Levy, A.
- New search for: Johnston, K.
- New search for: Daoust, A.
- New search for: Ignaszewski, A.
- New search for: Rogula, B.
- New search for: Lakzadeh, P.
- New search for: Fortier, J.
- New search for: Oh, P.
- New search for: Levy, A.
- New search for: Johnston, K.
- New search for: Daoust, A.
- New search for: Ignaszewski, A.
- New search for: Rogula, B.
- New search for: Lakzadeh, P.
- New search for: Fortier, J.
- New search for: Oh, P.
In:
Value in health
;
21
, 3
;
S103
;
2018
-
ISSN:
- Article (Journal) / Print
-
Title:PCV64 - THE DIRECT RESOURCE USE AND MEDICAL COSTS OF HEART FAILURE IN NOVA SCOTIA, CANADA
-
Contributors:Levy, A. ( author ) / Johnston, K. ( author ) / Daoust, A. ( author ) / Ignaszewski, A. ( author ) / Rogula, B. ( author ) / Lakzadeh, P. ( author ) / Fortier, J. ( author ) / Oh, P. ( author )
-
Published in:Value in health ; 21, 3 ; S103
-
Publisher:
- New search for: Elsevier Science B.V., Amsterdam
-
Publication date:2018-01-01
-
Size:S103
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 610.28
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 610.28 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 21, Issue 3
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 249
-
Affordability of New Technologies: The Next FrontierTowse, Adrian / Mauskopf, Josephine A. et al. | 2018
- 252
-
Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and CuresDanzon, Patricia M. et al. | 2018
- 258
-
The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care ValuePearson, Steven D. et al. | 2018
- 266
-
Resolving the "Cost-Effective but Unaffordable" Paradox: Estimating the Health Opportunity Costs of Nonmarginal Budget ImpactsLomas, James / Claxton, Karl / Martin, Stephen / Soares, Marta et al. | 2018
- 276
-
Paying for Cures: Perspectives on Solutions to the "Affordability Issue"Schaffer, Sarah Karlsberg / Messner, Donna / Mestre-Ferrandiz, Jorge / Tambor, Ellen / Towse, Adrian et al. | 2018
- 280
-
Affordability of Health Care: A Global CrisisWatkins, John B. et al. | 2018
- 283
-
Estimating the Learning Curve of a Novel Medical Device: Bipolar Sealer Use in Unilateral Total Knee ArthroplastiesKuznietsova, Victoria / Woodward, Robert S. et al. | 2018
- 295
-
Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational StudyRapp, Thomas / Andrieu, Sandrine / Chartier, Florence / Deberdt, Walter / Reed, Catherine / Belger, Mark / Vellas, Bruno et al. | 2018
- 304
-
Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer PatientsZhong, Yue / Valderrama, Adriana / Yao, Jianying / Donga, Prina / Bilir, Pinar / Neumann, Peter J. et al. | 2018
- 310
-
Cost-Effectiveness of Antibiotic Prophylaxis Strategies for Transrectal Prostate Biopsy in an Era of Increasing Antimicrobial ResistanceLee, Kyueun / Drekonja, Dimitri M. / Enns, Eva A. et al. | 2018
- 318
-
Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney DiseaseHabbous, Steven / Przech, Sebastian / Martin, Janet / Garg, Amit X. / Sarma, Sisira et al. | 2018
- 326
-
Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies?Malone, Daniel C. / Brown, Mary / Hurwitz, Jason T. / Peters, Loretta / Graff, Jennifer S. et al. | 2018
- 334
-
Sensitivity of Claims-Based Algorithms to Ascertain Smoking Status More Than Doubled with Meaningful UseHuo, Jinhai / Yang, Ming / Tina Shih, Ya-Chen et al. | 2018
- 341
-
What Is the Evidence from Past National Institute of Health and Care Excellence Single-Technology Appraisals Regarding Company Submissions with Base-Case Incremental Cost-Effectiveness Ratios of Less Than £10, 000/QALY?Carroll, Christopher / Houten, Rachel / Boland, Angela / Kaltenthaler, Eva / Dickson, Rumona et al. | 2018
- 351
-
The Importance of Model Structure in the Cost-Effectiveness Analysis of Primary Care Interventions for the Management of HypertensionPeñaloza-Ramos, Maria Cristina / Jowett, Sue / Sutton, Andrew John / McManus, Richard J. / Barton, Pelham et al. | 2018
- 364
-
Associations of Smoking, Physical Inactivity, Heavy Drinking, and Obesity with Quality-Adjusted Life Expectancy among US Adults with DepressionJia, Haomiao / Zack, Matthew M. / Gottesman, Irving I. / Thompson, William W. et al. | 2018
- i
-
Table of Contents| 2018
- S2
-
CE1 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO SITAGLIPTIN AND SAXAGLIPTIN BASED ON CARDIOVASCULAR OUTCOME TRIALSRamos, M. / Foos, V. / Ustyugova, A.V. / Hau, N. / Gandhi, P. / Lamotte, M. et al. | 2018
- S3
-
CN2 - PREDICTING UTILITY SCORES IN LOCALIZED PROSTATE CANCER: MAPPING FROM EPIC TO PORPUSZamora, V. / À, Pont / Garin, O. / Pardo, Y. / Ferrer Fores, M. et al. | 2018
- S4
-
CN6 - COST-EFFECTIVENESS MODEL OF MIDOSTAURIN (MIDO) VERSUS STANDARD OF CARE (SOC) IN PATIENTS WITH NEWLY DIAGNOSED FLT3 MUTATION-POSITIVE (FLT3+) ACUTE MYELOID LEUKEMIA (AML): A FRENCH PERSPECTIVECariou, C. / Tremblay, G. / Dolph, M. / Brandt, P.S. / Forsythe, A. et al. | 2018
- S5
-
CP4 - WEIGHTED AVERAGE CALCULATIONS FOR POPULATING COST-EFFECTIVENESS MODELS: HOW IGNORING THE MODEL'S CLINICAL PATHWAYS CAN SIGNIFICANTLY BIAS THE INCREMENTAL COST-EFFECTIVENESS RATIO (ICER)Van Vlaenderen, I. / Moeremans, K. / Van Bellinghen, L. et al. | 2018
- S6
-
DB1 - GLYCAEMIC CONTROL, CARDIOVASCULAR DISEASE AND MORTALITY IN TYPE 2 DIABETES (T2D) PATIENTS IN A REAL LIFE SETTING OVER TIME: POPULATION-BASED DATA FROM THE NETHERLANDSHouben, E. / Heintjes, E. / Cremers, S. / Beekman, W. / Beest F, Penning-van / Stehouwer, C. / Herings, R. et al. | 2018
- S8
-
HT3 - DESCRIPTION AND COMPARISON OF EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENTPisarczyk, K. / Hajjeji, B. / Rémuzat, C. / Espín, J. / Toumi, M. et al. | 2018
- S9
-
HT8 - DOES IQWIG MATTER? FREQUENCY OF DIVERGENT OPINIONS BETWEEN IQWIG AND THE G-BAMacaulay, R. / Mohamoud, Z. / Schmidt, B. et al. | 2018
- S10
-
MO1 - COMBINING INTERNALLY VALID TRIAL EVIDENCE WITH GENERALIZABLE REAL-WORLD DATA: INSIGHTS INTO EFFECTS, COSTS, AND COST-EFFECTIVENESS OF NOVEL TREATMENT SEQUENCES IN PATIENTS WITH MULTIPLE MYELOMABlommestein, H. / van Beurden-Tan, C. / de Groot, S. / Blijlevens, N. / Sonneveld, P. / Groot CA, Uyl-de / Zweegman, S. / Franken, M.G. et al. | 2018
- S11
-
ND2 - FUNCTIONAL LOSS ACROSS STAGES OF ALZHEIMER'STsong, W. / Jones, E. / Pike, J. / Bluff, D. et al. | 2018
- S12
-
PP4 - ONE SIZE DOES NOT FIT ALL: HETEROGENEOUS PATIENT PREFERENCES AND TRADEOFFS FOR ANTIRETROVIRAL THERAPY - RESULTS OF A DISCRETE CHOICE EXPERIMENTOstermann, J. / Derrick, C. / Yelverton, V. / Hobbie, A. / Weinhold, A. / Thielman, N. et al. | 2018
- S15
-
PCN5 - TREATMENTS OF RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER IN ROUTINE CLINICAL PRACTICE – A SYSTEMATIC REVIEWBhutani, M.K. / Rajora, P. / Soni, D. / Pan, J.J. et al. | 2018
- S16
-
PCN10 - ECONOMIC IMPACT OF MEDICATION ERRORS DETECTED IN ONCOLOGIC INPATIENTS AND OUTPATIENTS IN A MEXICAN HOSPITALMorales Perez, M. / Paladio-Hernandez, J.A. / Luna Mendoza, D. / Paredes-Garcia, P. / Munguia Juarez, L. / Sanchez Rodriguez, I. / Lopez-Luis, J. / Hernandez-Martinez, J. / Ramirez-Padilla, L. / Diaz-Rosales, S. et al. | 2018
- S17
-
PCN17 - INDIRECT TREATMENT COMPARISONS OF NIVOLUMAB VERSUS REGORAFENIB, CABOZANTINIB AND BEST SUPPORTIVE CARE AFTER TREATMENT WITH SORAFENIB FOR HEPATOCELLULAR CARCINOMARoskell, N. / Gregory, J. / Wisniewski, T. / Thompson, G.J. / De la Cruz, C. et al. | 2018
- S18
-
PCN23 - EFFICIENCY OF NIVOLUMAB TREATMENT AFTER PLATINUM CHEMOTHERAPY IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) IN SPAINSuarez, J. / Juarez-Garcia, A. / Shaw, J.W. / Contente, M. / Polanco, C. et al. | 2018
- S19
-
PCN30 - EVIDENCE GENERATION IN A EARLY ACCESS STRATEGY FOR TARGETED ONCOLOGY THERAPIES: A COMPARISON IN NON-SMALL CELL LUNG CANCERvan Hooijdonk, I.E. / Lai, L. / van Engen, A. et al. | 2018
- S20
-
PCN37 - MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF APALUTAMIDE AND ENZALUTAMIDE IN THE TREATMENT OF NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCERChowdhury, S. / Oudard, S. / Hadaschik, B.A. / Uemura, H. / Joniau, S. / Pilon, D. / Ladouceur, M. / Behl, A. / Liu, J. / Dearden, L. et al. | 2018
- S21
-
PCN43 - A TARGETED REVIEW OF NICE SINGLE TECHNOLOGY APPRAISALS (STAS) IN UROTHELIAL CANCER SINCE THE INTRODUCTION OF THE NEW CANCER DRUGS FUND (CDF)Adedokun, L. / Penaloza-Ramos, C. / Lee, J. et al. | 2018
- S22
-
PCN53 - STRUCTURED LITERATURE REVIEW OF THE PREVALENCE OF MICROSATELLITE INSTABILITY HIGH (MSI-H) AND DEFICIENT MISMATCH REPAIR (DMMR) AMONG SOLID TUMORSLorenzi, M. / Amonkar, M. / Zhang, J. / Mehta, S. / Liaw, K. et al. | 2018
- S23
-
PCN58 - MEDIAN SURVIVAL, MEAN SURVIVAL OR HAZARD RATIO: WHICH ENDPOINT IS THE MOST APPROPRIATE FOR PATIENTS, PHYSICIANS AND POLICY MAKERS?Ben-Aharon, O. / Magnezi, R. / Leshno, M. / Goldstein, D.A. et al. | 2018
- S25
-
PCN70 - ASSESSING THE BUDGET IMPACT OF INCLUDING SUNITINIB FOR THE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN ARGENTINAMacmullen, M. et al. | 2018
- S26
-
PCN75 - BUDGET IMPACT MODEL OF SUBCUTANEOUS TRASTUZUMAB COMPARED WITH INTRAVENOUS TRASTUZUMAB ON THE TREATMENT OF HER-2 POSITIVE BREAST CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEMKashiura, D. / Souza, P.V. / Garrido, S.D. / Nardi, E. / Alves, M. et al. | 2018
- S27
-
PCN80 - BUDGET IMPACT ANALYSIS WITH USE OF SUBCUTANEUS TRASTUZUMABPoquet-Jornet, J.E. / Carrera Hueso, J. / Crespo, C. / Cuesta-Grueso, C. / Ramón Barrios, M.A. / Gasent-Blesa, J.M. / Fortuny-Organs, B. et al. | 2018
- S30
-
PCN96 - INITIAL THERAPY FOR ADVANCED PROSTATE CARCINOMA (PCA) WITH A GNRH AGONIST (GNRHA) AND ANTAGONISTS - A RETROSPECTIVE ANALYSIS OF PRESCRIPTION PATTERNS AND HOSPITAL COSTS BASED ON GERMAN GKV [GESETZLICHE KRANKENVERSICHERUNG (STATUTORY HEALTH INSURANCE)] DATAHupe, M.C. / Hammerer, P. / Ketz, M. / Kossack, N. / Colling, C. / Merseburger, A.S. et al. | 2018
- S31
-
PCN103 - PREDICTED TREATMENT COSTS AND SAVINGS PER PATIENT OF KANJINTI® (TRASTUZUMAB BIOSIMILAR) VS. SUBCUTANEOUS (SC) AND INTRAVENOUS (IV) HERCEPTIN® AND OTHER TRASTUZUMAB BIOSIMILARS IN ITALYAgirrezabal, I. / Gaikwad, I. / Cirillo, L. / Lothgren, M. et al. | 2018
- S32
-
PCN108 - TARGETED LITERATURE REVIEW OF THE BURDEN OF ILLNESS IN UROTHELIAL CARCINOMAShah, M.V. / McGovern, A. / Hepp, Z. et al. | 2018
- S34
-
PCN121 - BSC COST IN TERMINAL CANCER PATIENTS IN KOREAPark, M. et al. | 2018
- S37
-
PCN138 - COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER IN ENGLANDTsoumani, E. / D'Oca, K. / Zhong, Y. / Prabhu, V.S. / Xu, R. / Li, H. et al. | 2018
- S38
-
PCN143 - HEALTH ECONOMIC EVALUATION OF BIOLOGIC AGENTS FOR METASTATIC COLORECTAL CANCER PATIENTS IN BRAZILCarvalho, A.C. / Cao, Q. / van Asselt, A. / Sasse, A.D. / Postma, M.J. et al. | 2018
- S39
-
PCN148 - COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB COMPARED TO TREATMENT OPTIONS FOR ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER PRIOR CHEMOTHERAPY - UPDATED RESULTSKourkoulas, N. / Athanasakis, K. / Kakouros, M. / Skroumpelos, A. / Kyriopoulos, J. et al. | 2018
- S40
-
PCN153 - COST-EFFECTIVENESS ANALYSIS OF APALUTAMIDE FOR TREATMENT IN NON- METASTASIS CASTRATION-RESISTANT PROSTATE CANCERZhou, Z. / Hu, X. et al. | 2018
- S41
-
PCN163 - COST-EFFECTIVENESS OF ADD-ON PERTUZUMAB COMBINED WITH TRASTUZUMAB AND DOCETAXEL VERSUS PLACEBO AS TREATMENT OF HER-2 POSITIVE METASTATIC BREAST CANCER IN CZECH REPUBLICDoležel, J. / Pour, M. / Skalický, D. / Fínek, J. et al. | 2018
- S42
-
PCN169 - A FLEXIBLE OPEN-SOURCE COST-EFFECTIVENESS MODEL FOR METASTATIC EGFR+ NON-SMALL CELL LUNG CANCERJansen, J.P. / Incerti, D. / Shafrin, J. / Frederickson, A.M. / Lakdawalla, D.N. / Reckamp, K.L. et al. | 2018
- S43
-
PCN174 - NEPA, AN ORAL FIXED COMBINATION OF NETUPITANT AND PALONOSETRON, IS A COST-EFFECTIVE INTERVENTION FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN GERMANY AND GREECEBourhis, F. / Eriksson, J. / Ruffo, P. / D'Agostino, P. / Turini, M. et al. | 2018
- S44
-
PCN179 - THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT ERYTHROPOIESIS-STIMULANTIG AGENTS FOR MANAGING CHEMOTHERAPY-INDUCED ANEMIA IN ADULT CANCER PATIENTS IN ACTUAL PRACTICE IN RUSSIAKrysanova, V. / Krysanov, I. / Ermakova, V. et al. | 2018
- S46
-
PCN192 - ROBOTIC VERSUS LAPAROSCOPIC DISTAL PANCREATECTOMY: A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS ANALYSISNuñez Alfonsel, J. / Ielpo, B. / Quijano, Y. / Vicente, E. / Hidalgo, A. et al. | 2018
- S47
-
PCN199 - HOW DO QUALITY-ADJUSTED LIFE YEARS IMPACT REIMBURSEMENT DECISION-MAKING IN THE UK?Farinella, M. / Rubinstein, J. / Inumerable, R.V. / Gizaw, N. / Ho, Y. et al. | 2018
- S48
-
PCN204 - A SYSTEMATIC REVIEW OF BARRIERS AND FACILITATORS TO PARTICIPATION IN SHARED DECISION MAKING IN CANCER CARE: AN INTERNATIONAL PERSPECTIVEKamal, K.M. / Covvey, J.R. / Mehta, Z. / Zacker, C. et al. | 2018
- S49
-
PCN210 - USING REAL WORLD DATA TO DETERMINE HEALTH SYSTEM COSTS OF A 5-YEAR NON-SMALL CELL LUNG CANCER COHORTSeung, S.J. / Hurry, M. / Walton, R.N. / Evans, W.K. et al. | 2018
- S50
-
PCN216 - CONTEMPORARY REAL-WORLD EVIDENCES ON ALK+ NSCLC PATIENTS IN ITALYTucci, C. / Trimarchi, C. / Urbinati, D. / Demma, F. / Fico, M. / Fioravanti, L. et al. | 2018
- S51
-
PCN221 - STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER TREATMENT PATTERNS AND COSTS: AN ONTARIO, CANADA ANALYSISSeung, S.J. / Hurry, M. / Walton, R.N. / Evans, W.K. et al. | 2018
- S52
-
PCN227 - ACCESS TO ESSENTIAL ANTINEOPLASTICS AND IMMUNOSUPPRESSIVESKazaryan, I. / Sevikyan, A. / Amirkhanyan, A. / Melikyan, M. et al. | 2018
- S53
-
PCN232 - VARIATION IN ACCESS TO PD-1 IMMUNOTHERAPIES IN EUROPELast, V. / Hickey, D.A. et al. | 2018
- S55
-
PCN245 - WHAT DRUGS SHOULD BE IN THE FOCUS OF COMPLEX EVALUATION IN PATIENTS WITH BREAST CANCER IN MOSCOWTolkushin, A. / Davydovskaya, M. / Ermolaeva, T. / Kokushkin, K. / Poliakova, K. et al. | 2018
- S56
-
PCN250 - ASSESSING THE REAL WORLD USAGE OF PD-1 INHIBITORS IN ADVANCED MELANOMA ACROSS EU5Rider, A. / Lewis, K. / Higson, O. et al. | 2018
- S58
-
PCN263 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH PROSTATE CANCER IN SPAIN.Solozabal, M. / De Prado, A. / Planellas, L. / Á, Baltasar-Sanchez / Carreño-Serra, A. / Callejo-Velasco, D. et al. | 2018
- S59
-
PCN268 - TREATMENTS AND HEALTH CARE UTILISATION (HCU) IN PATIENTS WITH RECURRENT OR METASTATIC (R/M) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) FOLLOWING INITIAL PLATINUM THERAPY IN THE UNITED KINGDOMParikh, R.C. / Kurosky, S. / Kaye, J.A. / Levine, C. / Hettle, R. / Shire, N. / Mann, H. / Wang, H. et al. | 2018
- S60
-
PCN274 - TIME TO PRICE CHANGE FOLLOWING HTA DECISIONSLiden, D. / Jao, R. / Adler, B.N. / Lockwood, C. / Reinaud, F. et al. | 2018
- S61
-
PCN280 - IMPACT OF SUBOPTIMAL CLINICAL EVIDENCE ON HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATIONSZou, D. / Desrosiers, N. / Wu, S. / Prawitz, T. / Tervonen, T. / Marsh, K. / Caro, J.J. et al. | 2018
- S62
-
PCN286 - INCREMENTAL COST-EFFECTIVENESS RATIO FOR THE ANTINEOPLASTIC DRUGS APPROVED AND REJECTED FOR THE VITAL AND ESSENTIAL DRUGS LIST IN 2017 IN RUSSIAOmelyanovskiy, V. / Avxentyeva, M. / Sura, M. / Savilova, A.G. / Khachatryan, G.R. et al. | 2018
- S63
-
PCN292 - CANCER DRUGS IN GERMANY: HTA DECISIONS OF NEW AND INNOVATIVE ONCOLOGY DRUGS IN GERMANY – AN ANALYSIS USING THE PRISMACCESS® DATABASEMayer, F. / Hodek, J. / Walzer, S. et al. | 2018
- S64
-
PCN298 - MANAGEMENT OF ANTIEMETIC TREATMENT FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV): PATIENTS', ONCOLOGISTS' AND NURSES' PERSPECTIVESDuracinsky, M. / Chassany, O. / Griffith, J. / Coblentz-Baumann, L. et al. | 2018
- S65
-
PCN303 - ASSESSING THE VALUE OF NOVEL IMMUNO-ONCOLOGY (I-O) THERAPIES: HOW CONSISTENT IS THE HEALTH TECHNOLOGY ASSESSMENT (HTA) BODIES' CONSIDERATION OF THE SURVIVAL BENEFIT IN THE ABSENCE OF LONG-TERM DATA?Jonsson, B. / Chao, D. / Toumi, M. / Child, A. / Morris, J. / Hertel, N. et al. | 2018
- S66
-
PCN310 - SURVIVAL IN CANCER CLINICAL TRIALS: A COMPARISON OF EMA APPROVALS AND NICE RECOMMENDATIONS.Filby, A. / Edwards, H.K. / Beggs, L. / O'Brien, S. et al. | 2018
- S67
-
PCN315 - IMPACT OF PRO DATA ON IQWIG BENEFIT RATINGS IN ONCOLOGYLie, X. / Kempf, L. / van Engen, A. et al. | 2018
- S68
-
PCN321 - COMPARISON OF RECOMMENDATIONS FOR CANCER DRUGS CARRIED OUT BY THREE HTA BODIES (2015-2018): NICE TECHNOLOGY APPRAISALS, GERMAN FEDERAL JOINT COMMITTEE AND SPANISH THERAPEUTIC POSITIONING REPORTRebollo, P. / Hashim, M. / Gottschalk, F. / Ortega, T. / Heeg, B. / Wilke, T. et al. | 2018
- S69
-
PCN326 - COMPARATIVE ANALYSIS OF ESMO MAGNITUDE OF CLINICAL BENEFIT SCALE VALUES ASSIGNED TO NSCLC CANCER DRUGS, VERSUS REAL WORLD DATA ON PRESCRIBING ACTIVITY AND LEVELS OF SATISFACTION IN THE EU5Caldeira, R. / Franceschetti, A. et al. | 2018
- S70
-
PCN333 - REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED (STAGE II-IV) OVARIAN CANCER CLASSIFIED AS RESISTANT OR REFRACTORY TO FRONTLINE PLATINUM-BASED THERAPYByrne, K. / Moon, R. / Chang, J. / Hubanova, P. / Doherty, J.P. / Cappelleri, J.C. et al. | 2018
- S72
-
PCN345 - HEALTH STATE UTILITIES IN METASTATIC NSCLC: A STUDY OF MULTIPLE IMMUNO-ONCOLOGY TRIALSHuang, M. / Chandwani, S. / Insinga, R. / Burke, T. / Pellissier, J. / Pickard, A.S. et al. | 2018
- S73
-
PCN350 - EVALUATION OF DISEASE-SPECIFIC SKIN SYMPTOM ITEMS ON SKINDEX-29 IN CUTANEOUS T-CELL LYMPHOMA PATIENTS TREATED WITH MOGAMULIZUMAB OR VORINOSTATHudgens, S. / Floden, L. / Leoni, M. / Nikonova, E. / Quaglino, P. et al. | 2018
- S74
-
PCN356 - HOW SHOULD WE VALIDATE UTILITY MAPPING ALGORITHMS BEFORE USE? AN EXAMPLE IN NON-SMALL CELL LUNG CANCERGregory, J. / Dyer, M. / Hoyle, C. / Mann, H. / Hatswell, A.J. et al. | 2018
- S75
-
PCN362 - UNDERSTANDING PATIENT AND CLINICIAN PERCEPTIONS OF CELL AND GENE THERAPY IN ONCOLOGY USING QUALITATIVE ANALYSES OF SOCIAL MEDIA DATAMerinopoulou, E. / Cooper, O. / Hareendran, A. / Booth, A. / Faulkner, E.C. / Spinner, D.S. / Bruno, A. / Arjunji, R. et al. | 2018
- S76
-
PCN368 - CONCORDANCE BETWEEN PATIENTS AND CLINICIANS' REPORTING OF SYMPTOMATIC ADVERSE EVENTS IN CANCER CLINICAL TRIALS: A SYSTEMATIC REVIEWSparano, F. / Aaronson, N. / Cottone, F. / Piciocchi, A. / La Sala, E. / Anota, A. / Deliu, N. / Kieffer, J.M. / Efficace, F. et al. | 2018
- S79
-
PCN383 - ESTIMATING THE HEALTH IMPACT OF INCREASING BREAST AND CERVICAL CANCER SCREENING IN THE NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM AMONG LOW-INCOME WOMEN IN THE UNITED STATESEkwueme, D.U. / Pollack, L.M. / Hung, M. / Khushalani, J.S. / Miller, J.W. / Chang, S. et al. | 2018
- S82
-
PCP6 - HOW TO INTRODUCE MULTI-INDICATION BASED PRICING IN FINLAND?Karppinen, M.L. / Ihalmo, P. / Hjortsberg, C. et al. | 2018
- S83
-
PCP13 - IMPACT OF OUTCOME BASED ANNUITIES ON SMALL BIOTECH COMPANIESNevins, J.F. / Colasante, W. / Rahmati, D. et al. | 2018
- S84
-
PCP19 - AN UPDATED NICE POSITION ON THE EQ-5D-5L VALUATION SETCooper, S. / Bouvy, J. / Boysen, M. / Robertson, J. et al. | 2018
- S86
-
PCP34 - BIOSIMILARS: WHAT'S THE ISSUE?Mahi, L. / Barral, G. et al. | 2018
- S88
-
PCP48 - STABILITY OF RESULTS IN SIMULATION BASED HEALTH ECONOMIC MODELSGal, P. / Kovacs, V. et al. | 2018
- S90
-
PCP60 - EVOLVING STRATEGIES FOR GENERATING, SYNTHESIZING, AND VISUALIZING REAL WORLD EVIDENCE IN RARE DISEASESSzabo, S.M. / Johnston, K.M. et al. | 2018
- S91
-
PCP65 - KEY CONSIDERATIONS FOR THE COLLECTION OF PATIENT REPORTED OUTCOME (PRO) DATA IN REAL WORLD (RW) STUDIESRylands, A.J. / Boxell, E. / Bottomley, C.J. et al. | 2018
- S93
-
PCV7 - COMPARATIVE EFFECTIVENESS OF ORAL PROSTACYCLIN PATHWAY DRUGS ON HOSPITALIZATION AMONG PATIENTS WITH PULMONARY HYPERTENSION: A RETROSPECTIVE ADMINISTRATIVE CLAIMS STUDY IN A MANAGED CARE POPULATION IN THE USTsang, Y. / Drake, W. / Pruett, J. et al. | 2018
- S94
-
PCV12 - SHOULD KCENTRA BE ADDED FOR TREATMENT IN EMERGENCY WARFARIN REVERSAL?Oh, J. / Tsitarava, M. / Loh, F.E. et al. | 2018
- S96
-
PCV26 - LIPID MODIFYING THERAPY AND LDL-C ACHIEVEMENTS IN A VERY HIGH CARDIOVASCULAR RISK COHORT OF PATIENTS MANAGED BY GENERAL PRACTITIONERS IN ITALYFanelli, F. / Gazzi, L. / Heiman, F. / Peduto, I. / Pegoraro, V. et al. | 2018
- S97
-
PCV33 - THE RATE OF CARDIOVASCULAR EVENTS IN DIABETIC PATIENTS IN COLOMBIARomero, M. / Marino, C. / Cruz, A.M. / Rigueros, J. et al. | 2018
- S98
-
PCV38 - BUDGET IMPACT OF ALIROCUMAB IN THE MANAGEMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS IN ARGENTINAGiorgi, M.A. / Boissonnet, C.P. / Micone, P.V. / Gallo, M. / Stuart, P. / Giglio, N.D. et al. | 2018
- S99
-
PCV43 - BUDGET IMPACT ANALYSIS OF THE INTRODUCTION OF A SINGLE-PILL COMBINATION OF ATORVASTATIN, PERINDOPRIL AND AMLODIPINE IN THE GREEK SETTINGStafylas, P. / Karaiskou, M. / Zouka, M. et al. | 2018
- S100
-
PCV49 - A REAL WORLD COST COMPARISON BETWEEN THOSE USING SALVIANOLATE INJECTION AND NOT AMONG CHINESE PATIENTS WITH CORONARY HEART DISEASE OR ANGINA PECTORIS: A RETROSPECTIVE DATABASE STUDYXu, Y. / Liu, H. / Gao, Y. / Xuan, J. et al. | 2018
- S102
-
PCV62 - THE 1-YEAR PRODUCTIVITY LOSS AND INDIRECT COSTS AFTER ACUTE CARDIOVASCULAR EVENTS IN POLANDDudek, D.Z. / Lamotte, M. / Sawicka, M. / Huczek, Z.J. / Depukat, R. / Rajtar-Salwa, R. / Krupiarz, M. / Duma, K. / Sidelnikov, E. et al. | 2018
- S103
-
PCV67 - STAR ANALYSIS AND FORECAST MODELLING TO ESTIMATE VALUE FOR MONEY OF ORAL ANTICOAGULANTSOrlowski, A. / Slater, R. / Ashton, R. / Glover, R. et al. | 2018
- S104
-
PCV74 - COST-EFFECTIVENESS ANALYSIS OF ROSUVASTATIN COMPARED TO ATORVASTATIN IN SPANISH PATIENTS AT MODERATE, HIGH, AND VERY HIGH CARDIOVASCULAR RISKGarcía-Goñi, M. / Fácila, L. / Cinza, S. / Pinto, X. / Cortes, X. / Prades, M. / Aceituno, S. et al. | 2018
- S105
-
PCV80 - COST-EFFECTIVENESS OF NOACS IN PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN THE CZECH REPUBLICKolek, M. / Weber, J. / Karbusicka, M. / Vothova, P. / Mazan, P. / Duba, J. et al. | 2018
- S106
-
PCV85 - COST-EFFECTIVENESS OF BETRIXABAN COMPARED WITH ENOXAPARIN OR FONDAPARINUX FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS IN HOSPITALISED ACUTE MEDICALLY ILL PATIENTS IN THE UNITED KINGDOMLaskier, V. / Guy, H. / Fisher, M. / Neuman, W.R. / Bucior, I. / Deitelzweig, S.B. / Cohen, A. et al. | 2018
- S107
-
PCV91 - VENOUS THROMBOEMBOLISM PROPHYLAXIS STRATEGIES FOR ELECTIVE TOTAL KNEE REPLACEMENT SURGERY: A COST-UTILITY ANALYSIS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATIONDawoud, D. / Wonderling, D. / Lewis, S. / Glen, J. / Griffin, X. / Reed, M. / Rossiter, N. / Stansby, G. / Hunt, B.J. / Chahal, J.K. et al. | 2018
- S108
-
PCV96 - HEALTHCARE RESOURCE UTLISATION IN PATIENTS ON LIPID-LOWERING THERAPIES OUTSIDE OF WESTERN EUROPE: FINDINGS OF THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY (ICLPS)Annemans, L. / Azuri, J. / Al-Rasadi, K. / Al-Zakwani, I. / Daclin, V. / Mercier, F. / Danchin, N. et al. | 2018
- S109
-
PCV103 - MANAGEMENT OF ATHEROGENIC DYSLIPIDEMIA IN REAL CLINICAL PRACTICE WITHIN THE SPANISH HEALTH SYSTEM ACCORDING TO CURRENT TREATMENT GUIDELINES: DESPEGA STUDYAceituno, S. / Millan, J. / Rodriguez, P. / Rodríguez de Miguel, M. / Melogno Klinkas, M. / Orera - Peña, M.L. et al. | 2018
- S110
-
PCV108 - PRESCRIBING CHOICE AND THE COST OF ANTICOAGULATION IN ATRIAL FIBRILLATION: A REAL WORLD STUDY COMPARING HEALTHCARE EXPENDITURE WITH WARFARIN AND APIXABANSchinle, P. / Keogh-Bootland, S. / du Feu, J. / Durno, K. / How, W.J. / Hill, N. / Gordon, J. / Sugrue, D. / Beresford, L. / Lister, S. et al. | 2018
- S111
-
PCV114 - PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH PRESCRIPTION OF NOVEL ORAL COAGULANTS IN A LARGE HEALTHCARE SERVICE PROVIDER IN ISRAELWeitzman, D. / Bourvine, L. / Tirosh, M. / Shalev, V. / Chodick, G. et al. | 2018
- S112
-
PCV120 - INDICATORS OF PRESCRIPTIVE APPROPRIATENESS AS A LEVER FOR PHARMACEUTICAL SUSTAINABILITY - THE CASE OF LOW MOLECULAR WEIGHT HEPARINSAndretta, M. / Degli Esposti, L. et al. | 2018
- S113
-
PCV127 - EFFECT OF LIPID TESTING INTERVAL ON CARDIOVASCULAR DISEASE AMONG NEWLY DIAGNOSED DYSLIPIDEMIA PATIENTSKo, A. / Choi, S. / Chang, J. / Park, S.M. et al. | 2018
- S114
-
PCV135 - NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS PRESCRIPTION MONITORING: HOW TO OPTIMIZE VIGILANCE IN STROKE PREVENTIONJacobs, M.S. / van Hulst, M. / Campmans, Z. / Tieleman, R.G. et al. | 2018
- S115
-
PCV145 - A SYSTEMATIC LITERATURE REVIEW (SLR) ON HEALTH STATE UTILITIES ASSOCIATED WITH ANGINA AND REVASCULARISATIONNatani, H. / Gogna, S. / Jindal, R. / Laires, P.A. / Cristino, J. et al. | 2018
- S116
-
PCV150 - HEALTH CARE RESOURCE USE AND QUALITY OF LIFE IN PATIENTS PRESCRIBED WITH SACUBITRIL/VALSARTAN IN PORTUGAL: A CROSS-SECTIONAL OBSERVATIONAL STUDY (PRIME STUDY)Afonso-Silva, M. / Laires, P.A. / Gonçalves, C. / Cary, M. / Guerreiro, J.P. / Romão, M. / Teixeira Rodrigues, A. et al. | 2018
- S117
-
PCV155 - EVALUATING THE IMPACT OF PHARMACIST INTERVENTION ON DISEASE KNOWLEDGE, ILLNESS PERCEPTIONS, AND BELIEF TOWARDS MEDICATIONS IN ACUTE CORONARY SYNDROME PATIENTS IN HONG KONGLee, V.W. / So, S.C. / Yeo, J. / Yan, B.P. et al. | 2018
- S119
-
PDB7 - THE EFFECT OF GLYCATED HEMOGLOBIN CONTROL ON DIABETIC FOOT COMPLICATIONSHammad, M.A. / Syed Sulaiman, S.A. / Sha'aban, A. / Mohamed Noor, D.A. et al. | 2018
- S120
-
PDB12 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS: SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONSBalijepalli, C. / Ayers, D. / Kandaswamy, P. / Ustyugova, A.V. / Pfarr, E. / Lund, S.S. / Druyts, E. et al. | 2018
- S122
-
PDB24 - BASELINE CHARACTERISTICS OF GERMAN DIABETES MELLITUS TYPE-2 PATIENTS WHO INITIATED INSULIN USAGE: A CLAIMS DATA ANALYSISGabler, M. / Picker, N. / Mueller, S. / Wilke, T. / Geier, S. / Försch, J. / Aberle, J. / Martin, S. / Riedl, M. et al. | 2018
- S123
-
PDB32 - SEX- AND SITE-SPECIFIC DIFFERENCES IN COLORECTAL CANCER RISK AMONG PEOPLE WITH TYPE 2 DIABETESOverbeek, J.A. / Kuiper, J.G. / van der Heijden, A.A. / Labots, M. / Haug, U. / Herings, R.M. / Nijpels, G. et al. | 2018
- S124
-
PDB40 - IMPACT OF DAPAGLIFLOZIN ON REDUCING ECONOMIC BURDEN OF TYPE 2 DIABETES &ENHANCEMENT PATIENT'S OUTCOMES AT COUNTRIES WITH HIGH INCIDENCE OF DIABETES EGYPT CASEAbotaleb, A. / Amin, M. et al. | 2018
- S125
-
PDB46 - CLINICAL AND ECONOMIC BURDEN OF TYPE 1 DIABETES IN REAL-LIFE SETTING IN SPAINSicras-Mainar, A. / Navarro-Artieda, R. et al. | 2018
- S126
-
PDB52 - ANNUAL COST OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TURKEYÖksüz, E. / Malhan, S. / Balbay, Y. / Bozkurt, E. / Ersoy, R. / Tetik, E. / Urganci, B. / Kamaci, E. / Cheynel, J. et al. | 2018
- S127
-
PDB58 - REIMBURSEMENT FOR TYPE 2 DIABETES MELLITUS PATIENTS HOSPITALIZED IN A MUNICIPAL HOSPITAL IN THE CZECH REPUBLICLoncak, V. / Bartak, M. / Rogalewicz, V. et al. | 2018
- S128
-
PDB64 - SHORT-TERM COST-EFFECTIVENESS OF SWITCHING TO INSULIN DEGLUDEC IN JAPANESE PATIENTS WITH TYPE 2 DIABETESLanger, J. / Wolden, M.L. / Shimoda, S. / Sato, M. / Araki, E. et al. | 2018
- S129
-
PDB69 - COST-EFFECTIVENESS ANALYSIS OF ADDING PIOGLITAZONE TO INSULIN REGIMEN IN TYPE2 DIABETES IN IRANDavari, M. / Khorasani, E. / Savari Shojaei, R. / Akbari, Sari A / Saiyarsarai, P. et al. | 2018
- S130
-
PDB74 - IDEGLIRA VERSUS IGLARLIXI FOR PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN: A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN THE CZECH REPUBLICRussel-Szymczyk, M. / Parekh, W. / Rychna, K. / Pöhlmann, J. / Hunt, B. et al. | 2018
- S131
-
PDB79 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIABogdanovic, M. / Fournier, M. / Vitezic, D. et al. | 2018
- S132
-
PDB84 - HETEROGENEITY OF TREATMENT EFFECT IN THE DIABETES PREVENTION PROGRAM: HIGH BASELINE RISK OF DEVELOPING DIABETES MAY PROVIDE A PLACE FOR METFORMIN IN DIABETES PREVENTION THAT USING OVERALL SAMPLE AVERAGE COSTS AND EFFECTS CONCEALSAlolayan, S. / Eguale, T. / Segal, A. / Doucette, J. / Rittenhouse, B. et al. | 2018
- S133
-
PDB89 - THE BURDEN OF PREGNANCY HYPERGLYCEMIA IN INDONESIAN WOMENFitria, N. / Utama, B. / Pradipta, I. / Schmidt, A. / van Asselt, A. / Postma, M.J. et al. | 2018
- S134
-
PDB95 - REAL WORLD EVIDENCE ON TYPE 2 DIABETES: IDENTIFICATION AND CHARACTERIZATION OF NON-INSULIN TREATED PATIENTS WHO FULFIL CONDITIONS FOR THAT TREATMENTAscenção, R. / Fiorentino, F. / Costa, J. / Gouveia, M. / Borges, M. et al. | 2018
- S135
-
PDB101 - THERAPY ADJUSTMENT IN ADULT T2DM PATIENTS WITH RENAL IMPAIRMENT TREATED WITH DPP-4 INHIBITORS IN THE UK: A RETROSPECTIVE COHORT STUDYSpanopoulos, D. / Poole, C. / Barrett, B. / Busse, M. / Roman, T. / Khunti, K. et al. | 2018
- S137
-
PDB114 - DRUG UTILIZATION STUDY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN AN ITALIAN REAL-WORLD SETTING: A RETROSPECTIVE STUDYDegli Esposti, L. / Perrone, V. / Saragoni, S. / Blini, V. / D'Avella, R. / Gasperini, G. / Lena, F. / Fanelli, F. / Gazzi, L. / Giorgino, F. et al. | 2018
- S138
-
PDB119 - PATIENT PREFERENCES AND HEALTH STATE UTILITIES ASSOCIATED WITH MEALTIME INSULIN CONCENTRATIONS AMONG PATIENTS WITH DIABETES IN ITALYMatza, L.S. / Osumili, B. / Stewart, K.D. / Perez, M. / Jordan, J. / Biricolti, G. / Romoli, E. / Losi, S. / Del Santo, S. / Spaepen, E. et al. | 2018
- S139
-
PDB125 - A DISCRETE CHOICE EXERCISE TO EVALUATE FACTORS DRIVING GROWTH HORMONE DEFICIENT (GHD) PATIENT PREFERENCES FOR INJECTION AND INJECTION DEVICE FEATURESMcNamara, M. / Westhead, H. / Gross, H. / Turner-Bowker, D.M. / Yaworsky, A. / Pleil, A. / Loftus, J.V. et al. | 2018
- S140
-
PDB132 - TYPE 2 DIABETES TREATMENT PATHS AND PATIENT OUTCOMES IN RESPONSE TO REIMBURSEMENT POLICY CHANGE IN FINLANDRuotsalainen, J. / Balcerzak, M. et al. | 2018
- S142
-
PGI8 - SYSTEMATIC LITERATURE REVIEW AND INDIRECT TREATMENT COMPARISON OF LINACLOTIDE VERSUS OTHER ORAL CONSTIPATION TREATMENTS IN PATIENTS WITH CHRONIC CONSTIPATIONOkumura, H. / Tang, W. / Iwasaki, K. / Shoji, S. / Odaka, T. / Nakajima, A. et al. | 2018
- S143
-
PGI13 - REAL-LIFE BUDGET IMPACT OF DIRECT-ACTING ANTIVIRALS AGAINST HEPATITIS C VIRUS IN AN SPANISH PUBLIC HOSPITAL PHARMACYMargusino-Framiñán, L. / Cid-Silva, P. / Mena-de-Cea, A. / Vazquez-Rodriguez, P. / Rodriguez-Osorio, I. / Lopez-Calvo, S. / Pernas-Souto, B. / Martin-Herranz, I. / Castro-Iglesias, A. et al. | 2018
- S147
-
PGI39 - DARVADSTROCEL IN THE MANAGEMENT OF COMPLEX PERIANAL FISTULAS: THE ROLE OF PATIENT REGISTRY DATA COLLECTION TO SUPPORT PERFORMANCE-BASED RISK SHARING AGREEMENTSSchmetz, A. / Petrakis, I. / Khalid, J.M. / Minda, K. / Agboton, C. / Rawson, K. / Baumgart, D.C. et al. | 2018
- S148
-
PGI44 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) REPORT POSITIVE EXPERIENCE AFTER PARTICIPATING IN AN ONLINE QUANTITATIVE PREFERENCE SURVEYCook, N.S. / Balp, M. / Chatterjee, S. / Nagar, S. / Chirilov, A. / Weiss, O. / Schattenberg, J.M. / Schmid, A. / Hirschfield, G. / Kautz, A. et al. | 2018
- S149
-
PGI48 - PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) HAVE WORSE HEALTH RELATED QUALITY OF LIFE (HRQOL) THAN MATCHED CONTROLS: RESULTS FROM THE 2016 EU5 NATIONAL HEALTH AND WELLNESS SURVEY (NHWS)Balp, M. / Krieger, N. / Przybysz, R. / Way, N. / Cai, J. / Zappe, D. / Mckenna, S.J. / Wall, G. / Janssens, N. / Tapper, E. et al. | 2018
- S151
-
PHP8 - THE ROLE OF GENERAL PRACTITIONERS IN TRAUMA CARE: VARIATION BY INJURY TYPE, REGION, PATIENT PROFILE, AND OVER TIMEHöglinger, M. / Knöfler, F. / Scholz, S. / Schaumann-von Stosch, R. / Eichler, K. et al. | 2018
- S152
-
PHP13 - USAGE OF DIETARY SUPPLEMENTS BY GYM VISITING ATHLETES – EFFECTS, AWARENESS AND CONSCIOUSNESSIpolyi, D. / Molnár, A. / Oláh, A. / Karácsony, I. / Pakai, A. / Brantmüller, É. / Boncz, I. / Breitenbach, Z. et al. | 2018
- S153
-
PHP19 - ANALYSIS OF ONE-DAY SURGERY INTERVENTIONS AMONG PATIENTS UNDER THE AGE OF 18 IN HUNGARYPónusz, R. / Boncz, I. / Németh, N. / Kovács, D. / Varga, V. / Molics, B. / Gresz, M. / Endrei, D. et al. | 2018
- S154
-
PHP25 - MENTAL HEALTH COMORBIDITIES AND ELEVATED RISK OF OPIOID USE IN ELDERLY BREAST CANCER SURVIVORS USING ADJUVANT ENDOCRINE TREATMENTSDesai, R.A. / Camacho, F. / Tan, X. / LeBaron, V. / Blackhall, L. / Balkrishnan, R. et al. | 2018
- S155
-
PHP31 - IMPACT OF EUROPEAN MEDICINES AGENCY (EMA) CLINICAL TRIAL TRANSPARENCY POLICIES ON HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS IN GERMANYJones, C. / Cocklin, S.L. et al. | 2018
- S156
-
PHP36 - EU5 AND PHARMACEUTICAL RESPONSES TO THE SPREAD OF CARBAPENEM-RESISTANT BACTERIA: A POLICY AND PIPELINE REVIEWCollings, H. / Palmer, T. / Tavella, F. et al. | 2018
- S157
-
PHP43 - EVIDENCE FOR HIGH RISK CLASS MEDICAL DEVICES VERSUS NEW DRUGS IN GERMANY: WHAT'S THE DIFFERENCE?Mueller, E. / Neeser, K. / Oelze, I. et al. | 2018
- S158
-
PHP48 - INTERNATIONAL REFERENCE PRICING OF PHARMACEUTICALS: APPLY LIBERALLY OR USE SPARINGLY?Lockwood, C. / Rodrigues, T. / Ando, G. et al. | 2018
- S159
-
PHP56 - EARLY ACCESS PROGRAMS: AN ANALYSIS SINCE THEIR ESTABLISHMENT IN ITALYD'Ausilio, A. / Seyed Khoei, N. / Lanati, E.P. et al. | 2018
- S160
-
PHP62 - HOME BREWED AUTOLOGOUS THERAPIES: CAN BIOPHARMA WIN THE WAR WITH DOMESTIC AUTOLOGOUS CELL & GENE THERAPY MANUFACTURERS?Khurana, S. / Kumar, A. / Sotou, D.S. et al. | 2018
- S161
-
PHP67 - CURRENT INITIATIVES & FUTURE OF E-HEALTH FUNDING PATHSKloc, K. / Lach, S. / Dusza, M. / Rémuzat, C. / Sediri, Y. / Palencia, R. / Abshagen, D. / Toumi, M. et al. | 2018
- S162
-
PHP72 - A NEW FRENCH FINANCIAL INCENTIVE TO BOOST INSULIN AND ETANERCEPT BIOSIMILARS PRESCRIBING: SIMULATION OF ECONOMIC IMPACTS FOR THE PUBLIC HOSPITALS OF PARISAdé, A. / Degrassat-Théas, A. / Bocquet, F. / Parent de Curzon, O. / Paubel, P. et al. | 2018
- S163
-
PHP78 - PRICING AND REIMBURSEMENT REFORMS IN SPAIN – A SYSTEMATIC ANALYSIS OF NATIONAL PRICING DECISIONS BY THE CIPMMacaulay, R. / Fernandez Dacosta, R. et al. | 2018
- S165
-
PHP93 - THE IMPACT OF SUPPLY CHAIN MARGINS AND VAT ON THE PRICES OF MEDICINES IN BULGARIA AND GREECECherneva, D. / Benisheva, T. et al. | 2018
- S166
-
PHP99 - OVER-THE-COUNTER MEDICINES USE AND ITS ASSOCIATION WITH RISK PERCEPTION AND SAFETY AMONG WOMEN VISITING COMMUNITY PHARMACIES IN MALAYSIAMittal, P. / Lai, K.Y. / Verma, R.K. / Hasan, S.S. et al. | 2018
- S167
-
PHP105 - A POPULATION-BASED DATA ANALYSIS OF DRUG PRESCRIPTION AND PATTERNS OF USE OF ANTIBIOTIC IN SOUTHERN ITALY POPULATIONMoreno Juste, A. / Guarino, I. / Russo, V. / Menditto, E. et al. | 2018
- S168
-
PHP110 - SUBSTANTIAL HEALTH GAINS FROM HEATH-SYSTEM-WIDE PATIENT BLOOD MANAGEMENT IMPLEMENTATION: ANALYTICS FOR EUROPEVandewalle, B. / Félix, J. / Ferreira, C. et al. | 2018
- S170
-
PHP121 - DISCRIMINATION IN ACCESS TO SCHEDULED SURGERY IN THE PORTUGUESE NHS: A SURVIVAL MODEL ANALYSISCima, J. / Almeida, A.S. et al. | 2018
- S171
-
PHP128 - 3F - FORMULA FOR FUNDING: RETHINKING THE PORTUGUESE HOSPITAL FUNDING SYSTEMLourenço, A. / Ventura, C. / Andrade, S. / Sousa, J. / Valadas, F. et al. | 2018
- S173
-
PHP139 - G-BA CONDITIONAL APPROVALS IN THE AMNOG PROCEDURE: IMPACT ON HTA OUTCOMES AND PRICEDehnen, J. / Petry, D. / Kruse, F. / Bercher, J. et al. | 2018
- S174
-
PHP144 - IMPACT OF A CREATIVE QUALITY IMPROVEMENT STRATEGY TO REDUCE PATIENT WAIT TIMES BETWEEN PRIMARY AND SPECIALITY CARE IN A TERTIARY, UNIVERSITY PUBLIC HOSPITAL IN PORTUGALCorreia, S. / Yantsides, C. / Amorim, A.P. / Monteiro, J.L. / Costa, L. / Gonçalves, A.M. / Azevedo, A. / Paiva, J.A. et al. | 2018
- S175
-
PHP151 - THE PERCEPTION OF THE PUBLIC ABOUT DISABILITY AND THE MEDICAL AND SOCIAL MODEL OF DISABILITY: A LITERATURE REVIEWFatoye, C. / Betts, A. / Odeyemi, A. / Fatoye, F. / Odeyemi, I. et al. | 2018
- S176
-
PHP156 - A SCENARIO ANALYSIS OF THE IMPACT OF TREATMENT SETTING ON HEALTH CARE COST AND TREATMENT OUTCOMESLewis, M. / Tavella, F. / Okhuoya, P. et al. | 2018
- S178
-
PHP167 - COUNTRY-LEVEL COST-EFFECTIVENESS THRESHOLD: INITIAL ESTIMATES IN REPUBLIC OF BELARUSKozhanova, I. / Sachek, M. et al. | 2018
- S180
-
PHP182 - EXTERNAL REFERENCE PRICING: CONSEQUENCES OF FRENCH PRICE DECREASES ON INTERNATIONAL TURNOVERLe Pen, C. / Sclison, S. / Ravonimbola, H. / Paolantonacci, J. / Baseilhac, E. / Savart, P. / Dorizon, D. / Vigneron, A. et al. | 2018
- S181
-
PHP188 - EVOLVING INDICATIONS – AN ANALYSIS OF INDICATION FIELDS OVER TIME BASED ON GERMAN PRESCRIBING INFORMATIONRavindra, S. / Boehler, Y. et al. | 2018
- S182
-
PHP193 - THE USE OF MEDTECH INNOVATION BRIEFINGS (MIBS) TO ENCOURAGE IMPLEMENTATION OF INNOVATIVE TECHNOLOGIES: A REVIEW OF PUBLISHED BRIEFINGS FROM 2014-2018Glen, F. / Pulfer, A. et al. | 2018
- S184
-
PHP206 - TUMOUR-AGNOSTIC AGENTS: ARE THEY FIT FOR REIMBURSEMENT?Khogeer, B. / Anjarwalla, N. / Doolub, N. / Grosvenor, A. et al. | 2018
- S185
-
PHP211 - ESTIMATION OF PHARMACEUTICAL CARE SERVICES IN UKRAINE: ISSUES AND WAYS FOR IMPROVEMENTDobrova, V. / Zupanets, I. / Shilkina, O. / Lishchyshyna, O. et al. | 2018
- S186
-
PHP217 - TIME TO MARKET AND PRICE COMPARISON FOR BIOSIMILAR DRUGS IN EU5López, N. / Prada, M. / Berard, I. / Schleich, W. / Melson, C. et al. | 2018
- S187
-
PHP222 - IDENTIFYING THE KEY DRIVERS AFFECTING THE REIMBURSEMENT OF THERAPEUTIC VACCINES IN EU5 COUNTRIES USING A WEB-BASED PORTAL TO ENGAGE PAYERSKumar Singh, K. / Clapton, G.S. / Narjal, M. / Yadav, V. / Shah, C.S. et al. | 2018
- S189
-
PHP233 - DIVERGENCE IN UK HTA RECOMMENDATIONS: NOT ALWAYS A NICE OUTCOMEGriffiths, E.A. et al. | 2018
- S190
-
PHP238 - CARER DISUTILITY: IS IT ACCURATELY CAPTURED IN NICE APPRAISALS?Ferizovic, N. / Marshall, J.D. et al. | 2018
- S191
-
PHP243 - DO DISEASE SEVERITY AND/OR QUALITY OF CLINICAL DATA INFLUENCE PRICING POLICY IN FRANCE? AN ANALYSIS ON ORPHAN DRUGS AND BLOOD CANCERS TREATMENTSVandewalle, C. / Charoy, M. / Heurtebis, J. / Desplanches, L. / Gauthier, M. / de Sauvebeuf, C. et al. | 2018
- S192
-
PHP252 - IS FACTOR ANALYSIS AS CREDIBLE AS OTHER TESTS OF DIFFERENCE AND ASSOCIATION FOR EVALUATING THE VALIDITY OF QUALITY OF LIFE MEASURES? ASSESSING THE CONVERGENT AND DISCRIMINANT VALIDITY OF THE WOMEN'S HEALTH QUESTIONNAIRE AGAINST THE EQ-5D-5L AND SF-6DKaambwa, B. / Ratcliffe, J. et al. | 2018
- S193
-
PHP258 - DEVELOPMENT OF A REAL WORLD EVIDENCE STUDY DESIGN TOOLXia, A. / Schaefer, C. / Szende, A. / Jahn, E. / Dunlop, W. et al. | 2018
- S194
-
PHP265 - LANDSCAPE ASSESSMENT OF A MENA HEALTHCARE DATABASE FOR USE IN HEALTH ECONOMICS MODELINGMaskineh, C. / Becker, R.V. / Kosremelli Asmar, M. / Bekhazi, H. / Sleilaty, G. et al. | 2018
- S195
-
PHP270 - POPULARITY OF NURSING PROFESSION AMONGST STUDENTS WHO ARE BEFORE THE CAREER CHOICEFerenczy, M. / Dudás, M. / Pakai, A. / Karácsony, I. / Boncz, I. / Rozmann, N. / Komlósi, K. / Oláh, A. et al. | 2018
- S197
-
PHP281 - THE METHODOLOGICAL DIFFERENCES OF EUROPEAN JOINT ASSESSMENT AND GERMAN HTA: AN EMPIRICAL APPROACHPanni, T. / Thiele, A. / Carls, A. / Wallstab, A. / Eberle, K. / Schleibner, S. et al. | 2018
- S198
-
PHP286 - RESPONSES OF ISPOR MEMBERS TO THE RECOMMENDATIONS OF THE SPECIAL TASK FORCE ON US VALUE ASSESSMENT FRAMEWORKSOyeye, O. / Johnson, K.I. et al. | 2018
- S199
-
PHP291 - SHAPING THE FUTURE OF EUROPEAN HEALTH TECHNOLOGY ASSESSMENTS: EXPERIENCES OF THREE PHARMACEUTICAL JOINT RAPID RELATIVE EFFECTIVENESS ASSESSMENTSWillemsen, A. / Estevão, S. / Dupree, R. et al. | 2018
- S200
-
PHP296 - MANAGED ACCESS AGREEMENTS (MAAS) AND CONTINUING DATA COLLECTION AFTER PROVISIONAL POSITIVE RECOMMENDATION FROM THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)Wordsworth, J. / Cork, D. / Curry, A. / Ralston, S. et al. | 2018
- S202
-
PHP307 - REIMBURSEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPEHanna, E. / Marre, C. / Toumi, M. et al. | 2018
- S203
-
PHP313 - ANALYSIS OF THE ANALYTICAL AND METHODOLOGICAL FRAMEWORK OF THE HEALTH ECONOMIC EVALUATION ASSESSMENTS DELIVERED IN FRANCECabout, E. / Launois, R. et al. | 2018
- S204
-
PHP319 - MANDATORY JOINT CLINICAL ASSESSMENT – WHAT IS THE ADDITIONAL INSIGHT FROM EU-NETHTA VS. EMA?Ecker, T. et al. | 2018
- S207
-
PHP337 - OFF-LABEL PRESCRIPTION OF DRUGS COMPARED TO PRESCRIPTION AFTER LABEL EXTENSION IN CHILDREN FOR GERMANYGohlke, A. / Kostev, K. / Kuschel, A. et al. | 2018
- S208
-
PHP342 - HOW TO MAXIMIZE THE EX-FACTORY PRICE IN PORTUGAL, WITH SIMULTANEOUS BENEFITS FOR PATIENTS AND PAYERS – AN INDUSTRY PERSPECTIVEHenriques, J. / Amorim, A. et al. | 2018
- S209
-
PHP348 - REGENERATIVE MEDICINE ADVANCED THERAPY: A BUDGET IMPACT ANALYSISHanna, E. / Marre, C. / Toumi, M. et al. | 2018
- S210
-
PHP353 - ROMANIAN EXPERIENCE WITH MANAGED ENTRY AGREEMENTS FOR DRUGSRadu, P. / Stoica, I. / Udroiu, P. et al. | 2018
- S211
-
PHP359 - IMPACT OF EXPEDITED MARKETING AUTHORISATION ON PRICING AND REIMBURSEMENT OUTCOMES FOR DRUGS IN THE US AND EU-5Izmirlieva, M.A. / Reinaud, F. / Ando, G. et al. | 2018
- S212
-
PHP365 - TRENDS AND CHARACTERISTICS OF MANAGED ACCESS AGREEMENTS APPROVED BY NICEMarsh, S.E. et al. | 2018
- S214
-
PIH7 - LONG-ACTING RECOMBINANT FSH (CORIFOLLITROPIN ALFA) VERSUS RECOMBINANT FSH AS ASSISTED REPRODUCTION TECHNIQUES IN THE MANAGEMENT OF INFERTILITY: A SYSTEMATIC REVIEW AND META-ANALYSISTaheri, S. / Varmaghani, M. / Heidari, E. / Yousefi, N. / Peiravian, F. et al. | 2018
- S216
-
PIH24 - MODELLED EFFECTS OF A PEDIATRIC TRIPLE-CHAMBER-BAG (3CB) SYSTEM ON PAYER COSTS AND CLINICAL OUTCOMES IN PRE-TERM NEONATES ACROSS FRANCE, GERMANY AND ITALYKriz, A. / Migliore, A. / Wright, A. / Piaggio, T. et al. | 2018
- S223
-
PIN18 - ESTIMATING THE BUDGET AND CLINICAL IMPACT OF INTRODUCING ISAVUCONAZOLE FOR THE TREATMENT OF PATIENTS WITH POSSIBLE INVASIVE ASPERGILLOSIS IN THE UNITED KINGDOMWeidlich, D. / Hicks, M.D. / Floros, L. / Patel, J. / Charbonneau, C. / Sung, A.H. et al. | 2018
- S224
-
PIN23 - CLINICAL AND ECONOMIC BURDEN OF INVASIVE MENINGOCOCCAL DISEASE IN FRANCEFievez, S. / Tin Tin Htar, M. / Goguillot, M. / Bénard, S. / Huang, L. et al. | 2018
- S225
-
PIN31 - ECONOMIC EVALUATION OF LETERMOVIR AS PROPHYLAXIS OF CLINICALLY SIGNIFICANT CYTOMEGALOVIRUS REACTIVATION AND DISEASE ON CMV-SEROPOSITIVE RECEPTORS OF ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANT IN THE PORTUGUESE SETTINGFerreira, J. / Pereira, R. / Schelfhout, J. / Jiang, Y. et al. | 2018
-
PHP370 - AMBULATORY CARE TRENDS IN THE EMERGENCY DEPARTMENTBuchenberger, J.D. / Noone, J.M. / Abrigo, M.B. et al. | 2018
-
PIH18 - DIRECT COST OF UNINTENDED PREGNANCIES IN JAPAN: ESTIMATING POTENTIAL IMPACTS WITH INCREASED USE OF MODERN CONTRACEPTIVESAkiyama, S. / Murata, T. / Kidoguchi, Y. / Osuga, Y. et al. | 2018
-
PHP361 - PIM AND EAMS: THE IMPACT OF PROMISING MEDICINE DESIGNATION IN ACHIEVING PATIENT ACCESSNikolettos, J. / Gapper, A. et al. | 2018
-
PIH2 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION FOLLOWING HYSTERECTOMYLeaper, D.J. / Holy, C.E. / Chen, B.P. / Ghosh, E. / Edmiston, C.E. et al. | 2018
-
PHP192 - HTA EDUCATIONAL NEEDS IN CENTRAL-EASTERN-SOUTH EUROPEAN (CESE) COUNTIRES – RESULTS OF JOC HTA PROJECTHermanowski, T.R. / Zawada, A. et al. | 2018
-
PHP187 - BEST PRACTICES FOR REAL WORLD EVIDENCE (RWE) COLLECTION FOR CELL AND GENE THERAPIESKhurana, S. / Kumar, A. et al. | 2018
-
PHP174 - ARE FIXED THERAPEUTIC-LEVEL SPENDING CAPS ADVISABLE FOR THE GREEK OUTPATIENT MARKET? METHODOLOGICAL ISSUES AND HEALTH POLICY PROPOSALSCharonis, A. / Papageorgiou, M. / Kontoudis, I. / Karokis, A. et al. | 2018
-
PHP162 - LICENCED ORPHAN MEDICINES EXPENDITURE IN TURKEYNacar, S. / Atikeler, K. / Beyan, A. / Safak Yilmaz, E. / Bayar, B. / Vural, I.M. et al. | 2018
-
PHP166 - TOOLS OF THE TRADE: PAYER APPROACHES TO HIGH PATIENT VOLUME, PREMIUM PRICED THERAPIESVassoler, H. / Spoors, J. et al. | 2018
-
PHP104 - PRESCRIPTION DRUG USE AND INAPPROPRIATE PRESCRIBING AMONG PREGNANT WOMEN IN SOUTH KOREAKim, A. / Lee, H. / Kang, H. et al. | 2018
-
PHP107 - THE STRUCTURE OF CONSUMPTION OF ANTIMICROBIAL DRUG FOR SYSTEMIC USE IN MULTIDISCIPLINARY HOSPITALS IN ST.PETERSBURG IN 2014-2015Gomon, J. / Kolbin, A. / Kurylev, A. et al. | 2018
-
PHP42 - EARLY ACCESS PROGRAMS: A COMPARISON BETWEEN FRANCE, GERMANY AND THE UNITED KINGDOMBen Younes, K. / Foix Colonier, A. / Amzal, B. / Angehrn, Z. / Karcher, H. et al. | 2018
-
PHP24 - ANALYSIS OF SPANISH THERAPEUTIC POSITIONING REPORTS PUBLISHED UNTIL 2017López, N. / Pomares, E. / Cuesta, M. et al. | 2018
-
PHP9 - PATIENT INVOLVEMENT IN THE DRUG LIFE CYCLE ACCORDING TO STAKEHOLDERS: EXPLORING THE GAP BETWEEN THEORY AND PRACTICEJanssens, R. / van Overbeeke, E. / Verswijvel, L. / Meeusen, L. / Coenegrachts, C. / Pauwels, K. / Dooms, M. / Stevens, H. / Simoens, S. / Huys, I. et al. | 2018
-
PHP5 - DEVELOPMENT OF THE PATIENT ORGANISATION SUBMISSION PROCESS IN THE NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE), IRELANDHanevy, A. / Gorry, C. / Tilson, L. / O'Leary, A. / Barry, M. et al. | 2018
-
PGI47 - OPIOID USAGE AND PATIENT-REPORTED PAIN SCORES IN IRRITABLE BOWEL SYNDROME PATIENTS: A RETROSPECTIVE ANALYSIS OF A LARGE U.S. ELECTRONIC HEALTH RECORD DATABASEPeyerl, F.W. / Shenoy, A. / Hayashida, D.K. / D'Souza, F.T. et al. | 2018
-
PGI42 - NON-PERSISTENCE WITH IMMUNOSUPPRESANT, ANTI-TUMOR NECROSIS FACTOR, AND ANTI-INTEGRIN AGENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE CLAIMS DATA ANALYSIS IN GERMANYWilke, T. / Groth, A. / Long, G.H. / Tatro, A.R. / Sun, D. et al. | 2018
-
PGI37 - UNIVERSAL ACCESS TO DIRECT-ACTING ANTIVIRALS FOR THE TREATMENT OF HEPATITIS C MANAGED BY THE HOSPITAL PHARMACY: CONTRIBUTIONS TO PUBLIC HEALTH AND PUBLIC EXPENDITUREFigueira, A. / Gomes, I. / Sequeira, C. / Silva, S. / Machado, F. / Figueiredo, J. / Rabadão, E. / Dinis, P. / Andreozzi, V. / Vandewalle, B. et al. | 2018
-
PDB122 - THE EFFECTS OF TYPE 2 DIABETES ON HEALTH-RELATED QUALITY OF LIFE IN THE FINNISH POPULATION AS MEASURED WITH EQ-5D-5LJalkanen, K. / Aarnio, E.J. / Lavikainen, P.T. / Jauhonen, H.M. / Enlund, H. / Martikainen, J.A. et al. | 2018
-
PDB116 - THE RELATIONSHIP BETWEEN POOR ADHERENCE AND HBA1C AND WEIGHT CHANGES IN PATIENTS WITH TYPE 2 DIABETESRamos, M. / Foos, V. / Ferrufino, C. / Yu-Isenberg, K. / Lamotte, M. et al. | 2018
-
PGI31 - PATTERNS OF ANTI-TNF ADOPTION AND DIFFUSION: REAL WORLD EVIDENCE FROM A 12-YEAR COHORT OF CROHN'S DISEASE AND ULCERATIVE COLITIS PATIENTS TREATED IN TERTIARY REFERAL MEDICAL CENTERS IN ISRAELSergienko, R. / Schwartz, D. / Odes, S. / Greenberg, D. et al. | 2018
-
PDB126 - FACTORS INFLUENCING FOOD CHOICES OF PEOPLE WITH TYPE 2 DIABETES: A Q METHODOLOGY STUDYHubens, K. / van Exel, N.J. et al. | 2018
-
PHP341 - ARE THERE ENOUGH REGULATIONS TO COMBAT THE POOR QUALITY POVIDONE-IODINE IN EGYPTHamdy El-sisi, G. / Emad, S. / Hamed, A. et al. | 2018
-
PHP330 - REAL-WORLD DATA COLLECTION ON MEDICAL DEVICES IN THE ERA OF VALUE-BASED HEALTHCARE: A LITERATURE REVIEWRizzo, E. / Buseghin, G. / Greco, T. / Murphy, J. / Pinciroli, M. / Mordenti, G. et al. | 2018
-
PHP329 - THE REGISTRY EVALUATION AND QUALITY STANDARDS TOOL (REQUEST) FOR HEALTH TECHNOLOGY ASSESSMENT FROM AN OUTCOMES ASSESSMENT PERSPECTIVEGimenez, E. / Espallargues, M. / Rodrigues, J. / Varela, L. / Patrick, H. / Jae, L. / Maja, V. / Guzina, I. et al. | 2018
-
PHP321 - THE HTA APPROACH OF NOVEL TREATMENTS IN THE CENTRAL EASTERN EUROPEAN COUNTRY FOR FIVE YEARS PERIOD (2013-2017): THE CASE OF BULGARIABenisheva Dimitrova, T. / Stoimenova, A. / Sidzhimova, D. / Atanasova, R. et al. | 2018
-
PHP306 - CAN GRADEPRO SUPPORT AND IMPROVE CHOICE OF OUTCOMES IN HEALTH TECHNOLOGY ASSESSMENT? REPORT ON A PILOT USE WITHIN THE EUNETHTA ASSESSMENT OF FEMTOSECOND LASER ASSISTED CATARACT SURGERY (FLACS)Ballini, L. / Bonvicini, L. / Bottazzi, P. / Eisenmann, A. / Formoso, G. / Giorgi Rossi, P. / Rosian-Schikuta, I. / Venturelli, F. / Vicentini, M. / De Laet, C. et al. | 2018
-
PHP297 - CHANGES IN ULTRA-ORPHAN DRUG ASSESSMENTS IN POLANDVaithyanathan, G. / Dekkers, R. / van Engen, A. et al. | 2018
-
PHP293 - ORPHAN DRUGS IN GERMANY - LESSONS LEARNED FROM AMNOG, BEST AND WORST PRACTICES AND STRATEGIC IMPLICATIONSKirchmann, T. / Ewald, A. / Schönermark, M. et al. | 2018
-
PHP275 - ORPHAN MEDICINAL PRODUCTS GIVEN AN INITIAL NEGATIVE RECOMMENDATION BY NICE'S STA PROCESS BUT APPROVED FOLLOWING RE-EVALUATION IN ENGLANDForsyth, C. et al. | 2018
-
PHP285 - EXPERTS IN HEALTH TECHNOLOGY ASSESSMENT ARE CONCERNED ABOUT THE TRANSLATION FROM EVIDENCE TO DECISION-MAKINGShih, T. / Toor, K. / Yoon, L. / Barron, R. / Cope, S. / Huber, C. / Arellano, J. / Jansen, J.P. et al. | 2018
-
PHP287 - GERMAN EARLY BENEFIT ASSESSMENTS OF ORPHAN DRUGS UNDER FULL DOSSIER CONDITIONSKirchmann, T. / Schönermark, M. / Ewald, A. et al. | 2018
-
PHP240 - HEALTH TECHNOLOGY ASSESSMENTS OF BEVACIZUMAB BIOSIMILARS: COULD A DEMONSTRATION OF COST-EFFECTIVENESS CHANGE THE RECOMMENDATION FOR REIMBURSEMENT VERSUS THE ORIGINATOR?Hnoosh, A. / Courmier, D.F. et al. | 2018
-
PHP244 - BRIDGING THE GAP: ENSURING FAIR ASSESSMENT OF ORPHAN TREATMENTS BY HEALTH TECHNOLOGY ASSESSMENTS IN ENGLANDFerizovic, N. / Hughes, T. et al. | 2018
-
PHP242 - AN ANALYSIS OF THE TIMELINES THROUGHOUT THE REIMBURSEMENT PATHWAY FOR DRUGS IN IRELANDConnolly, E. / Lamrock, F. / O'Donnell, H. / Walsh, C. / Tilson, L. / Barry, M. et al. | 2018
-
PDB93 - IMPACT OF CARDIOVASCULAR DISEASE ON HEALTHCARE RESOURCE UTILIZATION IN PATIENTS WITH TYPE 2 DIABETES IN A REAL WORLD SETTINGWeng, W. / Tian, Y. / Kong, S.X. / Ganguly, R. / Hersloev, M. / Brett, J. / Hobbs, T. et al. | 2018
-
PDB86 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN BULGARIABogdanovic, M. / Mihajlović, J. / Fournier, M. et al. | 2018
-
PDB60 - COST-CONSEQUENCE ANALYSIS FOR RECOMBINANT HUMAN GROWTH HORMONE TREATMENT ADMINISTERED VIA DIFFERENT DEVICES IN CHILDREN WITH GROWTH HORMONE DEFICIENCY IN ITALYCentonze, C. / Foo, J. / Vlachaki, I. / Novelli, P. et al. | 2018
-
PDB59 - COST-EFFECTIVENESS OF SWITCHING TO INSULIN DEGLUDEC (IDEG) U100 FROM CURRENTLY AVAILABLE BASAL INSULINS IN BELGIUM BASED ON EVIDENCE FROM REAL-WORLD CLINICAL PRACTICEOlivieri, A. / Vandebrouck, T. / Hvid, C. et al. | 2018
-
PDB48 - ANNUAL COST OF ILLNESS OF ISCHEMIC STROKE IN TYPE 2 DIABETIC PATIENTS IN TURKEYÖksüz, E. / Malhan, S. / Balbay, Y. / Bozkurt, E. / Ersoy, R. / Tetik, E. / Urganci, B. / Kamaci, E. / Cheynel, J. et al. | 2018
-
PDB29 - TYPE 2 DIABETES: DISCONTINUATION OF ANTIDIABETIC DRUG DISPENSING 8 YEARS AFTER STARTING TREATMENT: A NATIONWIDE COHORT STUDY USING THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS)Aguade, A. / Gastaldi-Menager, C. / Karsenty, D. / Semenzato, L. / Fontaine, P. / Fagot-Campagna, A. et al. | 2018
-
PDB37 - BUDGET IMPACT ANALYSIS OF THE ADULT TYPE 1 DIABETES MELLITUS NATIONAL CLINICAL GUIDELINE IN IRELANDCarty, P. / O'Neill, M. / Harrington, P. / Smith, S. / Ryan, M. et al. | 2018
-
PDB2 - COMPARISON OF ATORVASTATIN AND SIMVASTATIN EFFECT ON GLYCATED HEMOGLOBIN CONTROL AMONG OUTPATIENTS WITH TYPE 2 DIABETES MELLITUSHammad, M.A. / Syed Sulaiman, S.A. / Aziz, N.A. / Mohamed Noor, D.A. et al. | 2018
-
PCV112 - PATTERN OF USE OF ANTIHYPERTENSIVE DRUGS IN TWO EUROPEAN COUNTRIES: COMPARISON OF THE INDEX THERAPIES AND PERSISTENCEMalo, S. / Aguilar, I. / Russo, V. / Feja, C. / Orlando, V. / Rabanaque, M. / Lallana, M. / Menditto, E. et al. | 2018
-
PCV116 - DISCONTINUATION AND HEALTH CARE RESOURCE UTILISATION IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS TREATED WITH APIXABAN OR WARFARIN IN ENGLANDGraham, S. / Raluy-Callado, M. / Donaldson, R. / Colby, C. / Carroll, R. / Nordstrom, B. / Stynes, G. / Hill, N. / Ramagopalan, S. / Alikhan, R. et al. | 2018
-
PCV107 - MULTI-CRITERIA DECISION ANALYSIS (MCDA) - DISCUSSION ABOUT THE INCORPORATION OF RIOCIGUAT IN THE TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) UNDER THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEM (SUS)Carvalho, D.N. / Etto, H.Y. / Kim, H.S. / Nakada, C. / ÉJ, Peixoto de Miranda / Tannus, G. et al. | 2018
-
PCV99 - ANALYSIS OF MEAN AGE OF PATIENTS REGISTERED WITH ACUTE MYOCARDIAL INFARCTION IN HUNGARY, 2010-2017Németh, N. / Endrei, D. / Elmer, D. / Horváth, L. / Csákvári, T. / Pónusz, R. / Boncz, I. et al. | 2018
-
PCV81 - COST-EFFECTIVENESS ANALYSIS OF CLOPIDOGREL VERSUS ASPIRIN FOR HIGH-RISK PATIENTS WITH ESTABLISHED PERIPHERAL ARTERIAL DISEASE IN CHINALin, Z. / Zhang, L. / Yang, X. / Liu, L. / Xuan, J. et al. | 2018
-
PCN261 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH COLORECTAL CANCER IN SPAINPlanellas, L. / Solozabal, M. / Barrull, C. / De Prado, A. / Canal-Díaz, N. / Gómez-Navarro, V. et al. | 2018
-
PCN275 - HOW DO HTA DECISIONS FOR NEW DISEASE CONDITIONS IMPACT TIME TO PRICE CHANGES?Liden, D. / Jao, R. / Adler, B.N. / Lockwood, C. / Reinaud, F. et al. | 2018
-
PCN218 - PERSONALIZED THERAPY DEVELOPMENT IN NSCLC DEMONSTRATES INTERSECTION BETWEEN INNOVATION AND POSITIVE COVERAGE DECISIONSEslami, N. / Lehmann, H. / Garfield, S. / Erickson, G. et al. | 2018
-
PCN226 - BIOSIMILARS AND THE REGULATION OF ONCOLOGICAL PREPARATIONS IN GERMANYWalendzik, A. / Wasem, J. / Altin, S. / Bauer, C. / May, U. et al. | 2018
-
PCN155 - COST-EFFECTIVENESS OF CPX-351 VERSUS 3+7 AMONG PATIENTS <60 YEARS OF AGE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) IN THE UNITED KINGDOM (UK)Kansal, A. / Reifsnider, O. / Khankhel, Z. / Todorova, L. / Dorman, E. / Coughlan, A. / Hoog, M. / Villa, K. et al. | 2018
-
PCN152 - COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEYÖksüz, E. / Malhan, S. / Yanik, L. / Koc, E. / Erdogan-Ciftci, E. / Guler, B. / Orfanos, P. et al. | 2018
-
PCN175 - BRENTUXIMAB VEDOTIN COMPARED WITH STANDARD THERAPY FOR PATIENTS WITH ADVANCED-STAGE HODGKIN'S LYMPHOMA: A COST-EFFECTIVENESS ANALYSISRaymakers, A. / Costa, S. / Peacock, S.J. / Regier, D. et al. | 2018
-
PCN141 - COST-EFFECTIVENESS ANALYSIS OF OBINUTUZUMAB FOR THE TREATMENT OF PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED FOLLICULAR LYMPHOMA IN GREECEVellopoulou, K. / Tzanetakos, C. / Theodoropoulou, T. / Akratos, A. / Maniadakis, N. et al. | 2018
-
PCN131 - ASSESSING THE REAL-WORLD COST OF CARE IN PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER (MTNBC) IN THE UNITED STATESSkinner, K.E. / Dufour, R. / Haiderali, A. / Huang, M. / Schwartzberg, L.S. et al. | 2018
-
PCN134 - USE OF LIQUID BIOPSY IN METASTATIC NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION: A COST CONSEQUENCE ANALYSIS.Gancitano, G. / Almeida Gerolami, G. / Ravasio, R. / Cortinovis, L.D. / Dionisi, M. et al. | 2018
-
PCN120 - EPIDEMIOLOGY AND COSTS OF NON-SMALL CELL LUNG CANCER (NSCLC) IN AUSTRIAWalter, E. / Hausberger, S. / Lazic-Peric, A. et al. | 2018
-
PCN105 - ECONOMIC BURDEN OF RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN FRANCELafuma, A. / Cotté, F. / Le Tourneau, C. / Emery, C. / Gaudin, A. / Torreton, E. / Gourmelen, J. / Bonastre, J. et al. | 2018
-
PCN101 - COSTS AND HEALTHCARE RESOURCE USE ASSOCIATED WITH MAINTENANCE THERAPY IN MULTIPLE MYELOMA: A SYSTEMATIC LITERATURE REVIEWCherepanov, D. / Kayaniyil, S. / Huang, H. / Romanus, D. / Labotka, R. / Zagadailov, E. / Khan, Z. et al. | 2018
-
PCN78 - EVALUATING THE ECONOMIC CONSEQUENCES OF NOVEL AGENTS FOR TREATING HODGKIN LYMPHOMA IN GREECESiskou, O. / Vasilakopoulos, T. / Galanis, P. / Tsirigotis, P. / Batsis, I. / Terpos, E. / Megalakaki, A. / Pouli, A. / Konstantakopoulou, O. / Karagkouni, I. et al. | 2018
-
PCN79 - DECISION IMPACT OF A 21-GENE SIGNATURE IN EARLY BREAST CANCER: A NATURAL EXPERIMENT USING ROUTINE DATATramonti, G. / Gray, E. / Sims, A.H. / Hall, P.S. et al. | 2018
-
PCN57 - THE ASSOCIATION BETWEEN METFORMIN EXPOSURE AND SURVIVAL AMONG DIABETIC PATIENTS WITH NON-SMALL CELL LUNG CANCERRuban, C. / Blanchette, C.M. / Howden, R. / Kowalkowski, M. / Marino, J. / Saunders, W.B. et al. | 2018
-
PCN21 - COMPARATIVE EFFICACY OF NIVOLUMAB±IPILIMUMAB VERSUS STANDARD OF CARE (SOC) FOR THIRD-LINE (3L) PATIENTS WITH RECURRENT SMALL CELL LUNG CANCER (SCLC) USING POPULATION-ADJUSTED INDIRECT COMPARISONCope, S. / Popoff, E. / Keeping, S. / Goldgrub, R. / Jansen, J.P. / Penrod, J.R. / Abraham, P. / Camidge, D.R. / Korytowsky, B. / Gu, T. et al. | 2018
-
PP3 - TUNING INTO WHAT PATIENTS SAY ABOUT CLINICAL TRIALS WHEN SCIENTISTS AND CLINICIANS ARE NOT LISTENING: IMPLICATIONS FOR RECRUITMENTHalhol, S. / Booth, A. / Pan, S. / Cox, A. / Merinopoulou, E. et al. | 2018
-
ND4 - COST-EFFECTIVENESS EVALUATION OF THE INTRA-DUODENAL CONTINUOUS LEVODOPA INFUSION IN ADVANCED AND SEVERE PARKINSON'S DISEASECabout, E. / Kabeshova, A. / Launois, R. / Houeto, J. et al. | 2018
-
PCN171 - A COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS ANASTROZOLE AS FIRST-LINE THERAPY FOR OESTROGEN RECEPTOR-POSITIVE LOCALLY ADVANCED AND METASTATIC BREAST CANCERDavies, A.D. / Chang-Douglass, S. et al. | 2018
-
PCV29 - REAL-WORLD DOAC AND VKA USE: THE PHARMO-ANTICOAGULATION COHORTSmits, E. / Evers, J. / Penning-van Beest, F.J. / Herings, R.M. / Bezemer, I.D. et al. | 2018
-
PCV3 - IMPROVING ASPIRIN TOXICITY THROUGH PRECISION MEDICINESha'aban, A. / Zainal, H. / Muhamad, A.S. / Hammad, M.A. / Ibrahim, B. et al. | 2018
-
PCV32 - TRENDS IN THE INPATIENT CARE OF CORONARY HEART DISEASE IN 2005-2015Wahler, S. / Koll, C. / Müller, A. et al. | 2018
-
PCP47 - TAMING THE TORNADO CHART: SIMPLIFYING ONE-WAY SENSITIVITY ANALYSES FOR LARGE-SCALE MULTI-PARAMETER MODELSO'Day, K. / Mezzio, D. et al. | 2018
-
PCP15 - WHY EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT MAY FAIL?Pisarczyk, K. / Hajjeji, B. / Rémuzat, C. / Espín, J. / Toumi, M. et al. | 2018
-
PCN371 - HEALTH RELATED QUALITY OF LIFE IN CERVIX-UTERI CANCER WOMEN TREATED IN A MEXICAN THIRD LEVEL PUBLIC FACILITYGonzalez-Barba, F. / Sat-Muñoz, D. / Balderas-Peña, L. / Trujillo-Hernández, B. / Martinez-Herrera, B. / Bayardo-López, L.H. / López-Almaraz, L.M. / Salazar-Páramo, M. / Alvarado-Zermeño, A. / Hernández-Chávez, G.A. et al. | 2018
-
PCN337 - HR+/HER2− ADVANCED BREAST CANCER TREATMENT, DISEASE PROGRESSION, AND SURVIVAL IN ARGENTINA, BRAZIL, CHILE, COLOMBIA, AND MEXICOKurosky, S. / Levine, C. / Kaye, J.A. / Esterberg, E. / Suarez, L.A. / Zhan, L. / Iyer, S. et al. | 2018
-
PCP29 - BRAZILIAN PHARMACEUTICAL CLINICAL SERVICES: A DOCUMENTARY ANALYSISChagas, M.O. / Porto, C.C. / Chaveiro, N. / Noll, M. / Assis, D.L. / Chagas, F.A. / Chagas, V.O. et al. | 2018
-
PCN369 - RELATION OF HEALTH RELATED QUALITY OF LIFE WITH INDICATORS OF NUTRITIONAL STATUS IN HEAD AND NECK CANCER PATIENTS ATTENDED IN A MEXICAN THIRD LEVEL PUBLIC FACILITYMartinez-Herrera, B. / Sat-Muñoz, D. / Balderas-Peña, L. / Trujillo-Hernández, B. / Gonzalez-Barba, F. / Solórzano-Meléndez, A. / Bayardo-López, L.H. / Alvarado-Zermeño, A. / Hernández-Chávez, G.A. / Salazar-Páramo, M. et al. | 2018
-
PCN311 - EUROPEAN MARKET ACCESS CHALLENGES FOR RELAPSED REFRACTORY MULTIPLE MYELOMA TRIPLET THERAPIESStefani, I. / Brough, A. / McKee, E. / Lyons, E. et al. | 2018
-
PCN278 - DIVERSITY OF PATIENTS PATHWAYS WITH LUNG CANCER BETWEEN 4 FRENCH REGIONS: DEFINITION OF DISSIMILARITY MEASURESProdel, M. / Blein, C. / Fernandes, J. / Chouaid, C. et al. | 2018
-
PCN130 - COST ASSOCIATED WITH HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) – A RETROSPECTIVE CLAIMS DATA ANALYSIS IN GERMANYMayerhoff, L. / Lehne, M. / Hickstein, L. / Salimullah, T. / Prieur, S. / Thomas, S.K. / Zhang, J. et al. | 2018
-
PCN118 - THE BURDEN OF CANCER IN SPAINBadia, X. / Tort, M. / Camps, C. / Diaz Rubio, E. et al. | 2018
-
CN4 - COMPARISON OF MACHINE LEARNING ALGORITHMS FOR THE PREDICTION OF MISSING CROSS-SECTIONAL COST DATARueda, J. / Valencia, C.F. / Mullins, C.D. / Onukwugha, E. / Zhan, M. / Slejko, J.F. et al. | 2018
-
PCN386 - QUALITY OF LIFE OF CAREGIVERS OF CANCER PATIENTS BEFORE AND AFTER PATIENT ADMISSION TO AN INTENSIVE CARE UNITAl Rabayah, A.A. / Salmany, S. / Al Froukh, R. / AL Rayyan, M. / Al Najjar, B. / Nazer, L. et al. | 2018
-
PCP70 - REGENERATIVE MEDICINE: A PROPOSED CLASSIFICATION FOR HEOR BASED ON THERAPEUTIC STRATEGY AND TECHNOLOGY TYPEPurser, M. / Mladsi, D.M. et al. | 2018
-
PIH40 - THE HEALTH LITERACY OF IRANIAN PARENTS: A SURVEY IN TEHRAN CAPITAL CITYYousefi, N. / Peiravian, F. / Alavian, Y. et al. | 2018
-
PIH47 - SELF-MEDICATION PRACTICE IN PRIMARY DYSMENORRHEA AMONG MEDICAL AND PHARMACY STUDENTS IN UNAIZAH – KSA - A CROSS-SECTIONAL QUESTIONNAIRE STUDYAl-Rashidi, A. / Al-Subaie, S.A. / Farooqui, M. et al. | 2018
-
PIH14 - FACTORS ASSOCIATED WITH THE USE OF ANTIPYRETICS IN CHILDREN OF PARENTS IN A COHORT SAMPLE IN SAUDI ARABIAAlmogbel, Y. / AlQussiar, J. et al. | 2018
-
PIH27 - IRANIAN PARENTS' KNOWLEDGE ABOUT ANTIBIOTICSSharif, Z. / Yousefi, N. / Peiravian, F. / Alavian, Y. et al. | 2018
-
PHP178 - ROLE OF SUPPLEMENTARY AND COMPLEMENTARY PRIVATE HEALTH INSURANCE IN SELECTED COUNTRIESAlmasi, T. / Fasseeh, A.N. / Elezbawy, B. / George, M. / Abouelmaged, E. / Arnaiz, F. / Abaza, S.A. / Nagy, B. / Kaló, Z. et al. | 2018
-
PHP123 - REGIONAL DISPARITIES IN THE DISTRIBUTION OF HEALTH CARE FACILITIES: VISUALIZATION OF REGIONAL MEDICAL CARE SUPPORT HOSPITALSShimizu, S. / Shinjo, D. / Sakata, N. / Ishikawa, K.B. / Fushimi, K. et al. | 2018
-
PHP108 - DETERMINANTS OF THE UPTAKE OF ROTAVIRUS AND PNEUMOCOCCAL CONJUGATE VACCINES IN ETHIOPIAWondimu, A. / Postma, M.J. et al. | 2018
-
PHP109 - COST OF UNLICENCED AND ORPHAN MEDICINES IN TURKEY, KAZAKHSTAN AND POLANDAtikeler, K. / Goettsch, W. / Baran, A. / Gaitova, K. / Bayar, B. / Czech, M. / Leufkens, H.G. et al. | 2018
-
PHP77 - EFFECT OF NEW INDICATIONS ON THE PRICE DEVELOPMENT OF NEW MEDICINAL PRODUCTS IN GERMANYBot, D. / Linstaedt, J. / Ecker, T. et al. | 2018
-
PHP73 - FACTORS INFLUENCING THE DURATION OF MEDICINE PRICE NEGOCIATION IN FRANCEPetri, C. / Holscher, E. / Borget, I. / Bertin, L. et al. | 2018
-
PHP35 - AMNOG EARLY BENEFIT ASSESSMENT (EBA) AND MARKET PENETRATION OF NEW DRUGS FOR MELANOMA, MULTIPLE SCLEROSIS AND DIABETES MELLITUS IN GERMANYMathes, J. / Höer, A. et al. | 2018
-
PHP18 - COULD THE ONE-DAY SURGERY PLAY A SIGNIFICANT ROLE IN CATARACT WAITING LIST REDUCTION PROCESS IN HUNGARY?Pónusz, R. / Boncz, I. / Németh, N. / Kovács, D. / Varga, V. / Molics, B. / Gresz, M. / Endrei, D. et al. | 2018
-
PHP3 - SURVEY OF THE PATIENT ORGANISATION SUBMISSION PROCESS (POSP) TO THE NATIONAL CENTRE FOR PHARMACOECONOMICS (NCPE) IN IRELANDGorry, C. / Hanevy, A. / O'Leary, A. / Tilson, L. / Barry, M. et al. | 2018
-
PGI1 - ADVERSE EVENTS ASSOCIATED WITH THE TREATMENT OF INFLAMMATORY BOWEL DISEASE IN GERMANYWilke, T. / Groth, A. / Long, G.H. / Tatro, A.R. / Sun, D. et al. | 2018
-
PGI34 - A COST SAVING MEASURE FROM THE UTILISATION OF BIOSIMILAR INFLIXIMAB IN THE IRISH SECONDARY CARE SETTINGO'Brien, G.L. / Carroll, D.G. / Walshe, V. / Mulcahy, M. / Courtney, G. / O'Mahony, C. / Byrne, S. et al. | 2018
-
PGI43 - WHAT DO PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) VALUE AND NEED? RESULTS FROM A QUANTITATIVE PATIENT PREFERENCE STUDYCook, N.S. / Balp, M. / Chatterjee, S. / Nagar, S. / Chirilov, A. / Weiss, O. / Schattenberg, J.M. / Schmid, A. / Hirschfield, G. / Kautz, A. et al. | 2018
-
PGI29 - GENDER DIFFERENCES IN CLINICAL PROFILE AND HEALTHCARE UTILIZATION OF NON ALCOHOLIC FATTY LIVER PATIENTSGoldshtein, I. / Chodick, G. / Shibolet, O. et al. | 2018
-
PDB112 - TREATMENT AND DOSING PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES (T2D) INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) IN SEVERAL COUNTRIESNorrbacka, K. / Divino, V. / Boye, K. / Lebrec, J. / Dekoven, M. et al. | 2018
-
PDB113 - PSYCHOMETRIC EVALUATION OF A SELF-REPORTED MEDICATION ADHERENCE MEASURE ADAPTED TO COMMUNITY PHARMACY PRACTICE : THE QUESTIONNAIRE " TOP SCORE "Michiels, Y. / Bugnon, O. / Vergez, G. / Allaert, F. et al. | 2018
-
PDB104 - IMPACT OF DAPAGLIFLOZIN ON REDUCING ECONOMIC BURDEN OF DIABETES IN EGYPTAmin, M. / Abotaleb, A. et al. | 2018
-
PHP338 - PATIENT INVOLVEMENT IN CLINICAL PRACTICE GUIDELINE DEVELOPMENT PROCESSES: DOES REALITY ALIGN WITH INTENT?Desai, B. / Oehrlein, E. / Ganser, T.R. / Ngo, M. / Perfetto, E.M. et al. | 2018
-
PHP322 - REAL-WORLD DATA : WHAT ARE THE USE AND REQUIREMENTS IN HEALTH-ECONOMIC APPRAISALS IN REINSCRIPTION BY THE FRENCH HAUTE AUTORITE DE SANTE (HAS)?Petitjean, A. / Roze, S. et al. | 2018
-
PHP327 - CATEGORISATION OF OBSERVATIONAL STUDIES REQUESTED BY THE EMA AND SUBMITTED TO THE EUROPEAN UNION (EU) ELECTRONIC REGISTER OF POST-AUTHORIZATION STUDIES (PAS)Palacios, L. / De Cock, E. et al. | 2018
-
PHP332 - INTRODUCTION OF MOBILE HEALTH TECHNOLOGY AT THE PRIMARY HEALTHCARE LEVEL IN MONGOLIAChimeddamba, O. et al. | 2018
-
PHP308 - CONSIDERATION OF LEGAL ASPECTS IN HTA – CAN A SYSTEMATIC AND PRAGMATIC METHODOLOGICAL APPROACH BE IDENTIFIED IN GERMAN HTA?Siering, U. / Özdemir, D. / Thys, S. / Altenhofen, L. / Mischke, C. et al. | 2018
-
PHP276 - A REVIEW OF THE IMPACT OF INTEGRATED SCIENTIFIC ADVICE FOR THE OPTIMISATION OF EVIDENCE GENERATION FOR HTA APPRAISALSNg, T. / Ziomek, J. / Delaitre-Bonnin, C. / Bending, M.W. et al. | 2018
-
PHP257 - AN ANALYSIS AND FEASIBILITY ASSESSMENT OF INDICATION-SPECIFIC PRICING AS A MEANS TO IMPROVE PATIENT ACCESS TO MEDICINES AND REINFORCE INCENTIVES FOR INNOVATIONBaker, T. / Marinoni, G. / Houslay, D. / Tao, T. / Garbaz, O. / Malhotra, S. et al. | 2018
-
PHP261 - IMPACT OF DYNAMIC CHANGES OF THE DEFINITION OF THE APPROPRIATE COMPARATIVE THERAPY (ACT) ON MARKET ACCESS PERFORMANCE OF NEW ACTIVE SUBSTANCES IN GERMANYSchikowski, M. / Gibson, L. / Mrosowsky, T. / Schönermark, M. et al. | 2018
-
PHP219 - MEDICINRÅDET AND THE NEW HOSPITAL DRUG APPRAISAL PROCESS IN DENMARK – THE STORY SO FARRothwell, S. / Macaulay, R. et al. | 2018
-
PHP232 - A COMPARISON OF COST-EFFECTIVENESS ASSESSMENTS BETWEEN NICE AND SMC TECHNOLOGY APPRAISALSGriffiths, E.A. / Hendrich, J. et al. | 2018
-
PDB71 - ASSESSING THE RELATIVE COST-EFFECTIVENESS OF EMPAGLIFLOZIN AND CANAGLIFLOZIN FOR THE TREATMENT OF TYPE 2 DIABETES PATIENTS WITH EXISTING CARDIOVASCULAR DISEASE IN THE UKWebster, S. / Hau, N. / Ustyugova, A.V. / Kansal, A.R. / Reifsnider, O. et al. | 2018
-
PDB55 - ECONOMIC ANALYSIS OF TYPE-2 DIABETES MELLITUS IN VIETNAM: A RETROSPECTIVE STUDY AT A DISTRICT HOSPITAL, BA RIA - VUNG TAU PROVINCENguyen, T.T. et al. | 2018
-
PDB20 - PERSISTENCE TO LIRAGLUTIDE THERAPY IS ASSOCIATED WITH BETTER GLYCEMIC AND WEIGHT CONTROL IN PATIENTS WITH TYPE 2 DIABETESMelzer Cohen, C. / Chodick, G. / Nystrup Husemoen, L.L. / Rhee, N.A. / Shalev, V. / Karasik, A. et al. | 2018
-
PDB16 - COMPARE RENAL FUNCTIONAL PRSERVATION OUTCOME OF SGLT2 INHIBITOR VS DPP4 INHIBITOR IN PATIENTS WITH TYPE 2 DIABETES: A RETROSPECTIVE COHORT STUDY OF JAPANESE COMMERCIAL DATABASE WITH ADVANCED ANALYTICS APPROACHZhou, F.L. / Watada, H. / Tajima, Y. / Berthelot, M. / Kang, D. / Esnault, C. / Shuto, Y. / Maegawa, H. / Koya, D. et al. | 2018
-
PCV156 - CORRELATION OF THE DISEASE-SPECIFIC CSS/NYHA CLASSIFICATION WITH GENERIC HEALTH-RELATED QUALITY OF LIFE IN CORONARY ARTERY DISEASE PATIENTSLavikainen, P.T. / Hartikainen, J. / Miettinen, H. / Viljakainen, M. / Martikainen, J.A. / Tolppanen, A. / Roine, R.P. et al. | 2018
-
PDB8 - FACTORS ASSOCIATED WITH UNCONTROLLED GLYCEMIA AMONG OUTPATIENTS WITH TYPE 2 DIABETESHammad, M.A. / Syed Sulaiman, S.A. / Mohamed Noor, D.A. et al. | 2018
-
PCV75 - AN UPDATED COST-EFFECTIVENESS PAIRWISE ANALYSIS OF APIXABAN AND WARFARIN FOR STROKE PREVENTION IN PATIENTS WITH NON- VALVULAR ATRIAL FIBRILLATION IN FRANCELanitis, T. / Bregman, B. / Maunoury, F. / Prawitz, T. / Gaudin, A. / Cotté, F. et al. | 2018
-
PCV69 - COST-EFFECTIVENESS OF IVABRADINE AS A PHARMACOTHERAPY OPTION FOR PATIENTS WITH CONGESTIVE HEART FAILURE: A SYSTEMATIC REVIEWKumar, S. / Loh, F.E. et al. | 2018
-
PCV63 - ECONOMIC BURDEN ASSOCIATED WITH SECONDARY CARDIOVASCULAR (CV) EVENTS – A SYSTEMATIC LITERATURE REVIEWCholasamudram, S. / Yenamandra, J. / Jindal, R. / Cristino, J. et al. | 2018
-
PCN223 - WHAT UNDERLIES THE OBSERVED HOSPITAL VOLUME-OUTCOME RELATIONSHIP?Huguet, M. / Joutard, X. / Ray-Coquard, I. / Perrier, L. et al. | 2018
-
PCN239 - NICE AND THE CANCER DRUGS FUND: APPRAISING TREATMENTS FOR RARER CANCERS IN ENGLANDEdwards, H.K. / Kent, E. / Landells, L.J. et al. | 2018
-
PCN228 - REAL-WORLD USE OF PEMBROLIZUMAB AND NIVOLUMAB FROM CLINICAL TRIALS TO MARKET LAUNCH: WHAT CAN BE LEARNED?Bouee Benhamiche, E. / Le Bihan Benjamin, C. / Rocchi, M. / Negellen, S. / Bousquet, P.J. et al. | 2018
-
PDB11 - CHART REVIEW ANALYSIS OF INSULIN GLARGINE 300 AND INSULIN GLARGINE 100 USE IN FRANCE, SPAIN, AND GERMANYEscalada, J. / Bonnet, F. / Wu, J. / Bonnemaire, M. / Gupta, S. / Cambron-Mellot, M.J. / Nicholls, C. / Müller-Wieland, D. et al. | 2018
-
PCN217 - KEEPING UP WITH THE COMPARATORS: TRENDS IN TARGETED CANCER THERAPIES BECOMING RIGHT COMPARATORS FOR PAYERSWijnands, T. / Strydom, M. / Spinas, N. / van Engen, A. et al. | 2018
-
PCN172 - COST-EFFECTIVENESS ANALYSIS OF ALECTINIB IN UNTREATED ALK-REARRANGED NSCLC ITALIAN PATIENTSBellone, M. / Pradelli, L. / Masetti, L. / Recchia, A. / Orfanos, P. et al. | 2018
-
PCN182 - COST-EFFECTIVENESS RANDOMIZED STUDY OF LAPAROSCOPIC VERSUS OPEN BILATERAL INGUINAL HERNIA REPAIRNuñez Alfonsel, J. / Hidalgo, A. / Ielpo, B. / Quijano, Y. / Vicente, E. et al. | 2018
-
PCN135 - DOES PATIENT SELECTION CRITERIA TRANSLATE INTO COST SAVINGS IN PATIENTS WITH ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) AFTER CHEMOTHERAPY FAILURE IN SPAIN?Ramon, A. / Paladio, N. / Male, N. et al. | 2018
-
PCN107 - BURDEN AND COSTS OF ACUTE MYELOID LEUKAEMIA IN PORTUGALGuerreiro, R. / Miguel L, Silva / Costa, J. / Paquete, A.T. / Alarcão, J. / Fiorentino, F. / Borges, M. et al. | 2018
-
PCN88 - NET IMPACT ANALYSIS OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN THE TREATMENT OF ADULTS WITH MULTIPLE MYELOMA FOR QUEBECPettigrew, M. / Garces, K. et al. | 2018
-
PCN113 - EVALUATING THE ECONOMIC IMPACT OF NOVEL AGENTS FOR TREATING MULTIPLE MYELOMASiskou, O. / Terpos, E. / Galanis, P. / Vasilakopoulos, T. / Tsirigotis, P. / Batsis, I. / Megalakaki, A. / Pouli, A. / Konstantakopoulou, O. / Karagkouni, I. et al. | 2018
-
PCN104 - ECONOMIC ANALYSIS OF COSTS AND RESOURCE CONSUMPTION OF IXAZOMIB IN PATIENTS WITH RELAPSED / REFRACTORY MULTIPLE MYELOMA IN AUSTRIAWalter, E. / Lazic-Peric, A. / Schalle, K. / Voit, M. et al. | 2018
-
PCN76 - BUDGET IMPACT ANALYSIS OF AFATINIB FOR THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC NON–SMALL-CELL LUNG CANCER IN CHINAZhang, Y. / Samuelsen, C.H. / Griebsch, I. / Yao, Z. et al. | 2018
-
PCN61 - REAL-WORLD PROGRESSION-FREE SURVIVAL OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER: RESULTS OF A CLAIMS DATA STUDY OF PATIENTS IN GERMANYCizova, D. / Gottschalk, F. / Mueller, S. / Myers, D. / Wilke, T. et al. | 2018
-
PCN64 - REVIEW OF NICE HTA SUBMISSIONS INCLUDING METHODOLOGIES ADJUSTING FOR OVERALL SURVIVAL IN THE PRESENCE OF TREATMENT SWITCHINGGurskyte, L. / Muresan, B. / Kulakova, M. / Postma, M.J. / Ouwens, M.J. / Heeg, B. et al. | 2018
-
PCN33 - SYSTEMATIC LITERATURE REVIEW OF REAL-WORLD EVIDENCE (RWE) STUDIES FOR FIRST-LINE TREATMENTS IN ADVANCED OR METASTATIC RENAL CELL CARCINOMABregman, C. / Supiot, R. / Pacou, M. / Doan, J. / Dale, P. / Malcolm, B. et al. | 2018
-
QL2 - HEALTH UTILITY OF PATIENTS WITH TYPE 2 DIABETES AND VARIOUS SINGLE AND MULTIPLE COMPLICATIONS IN CHINA: A NATIONWIDE SURVEYWang, P. / Li, C. et al. | 2018
-
PCN14 - COMPARATIVE ANALYSIS OF PROFILES OF STAGE IIIB/IV NSCLC PATIENTS BY TIME FROM DIAGNOSIS TO FIRST TREATMENT IN THE UNITED STATESDaSilva, C. / Noone, J.M. / Wriede, V. et al. | 2018
-
QL1 - VALIDATION OF PROMIS PREFERENCE SCORE (PROPR) IN GERMAN PATIENTS WITH RHEUMATOLOGICAL CONDITIONSKlapproth, C.P. / Obbarius, A. / Merbach, M. / Rose, M. / Fischer, F. et al. | 2018
-
PCV42 - A PHARMACOECONOMIC ANALYSIS OF THE USE OF APIXABAN FOR THE PREVENTION OF STROKE AND SYSTEMIC EMBOLISM IN RUSSIAN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATIONRyazhenov, V.V. / Gorokhova, S.G. / Gorokhov, V. et al. | 2018
-
PCV24 - SAFETY AND EFFECTIVENESS OF CONTEMPORARY P2Y12 INHIBITORS IN EAST ASIAN PATIENTS WITH ACUTE CORONARY SYNDROMES: A NATIONWIDE POPULATION-BASED COHORT STUDYYun, J.E. et al. | 2018
-
PCV27 - HEART FAILURE SIGNS AND SYMPTOMS AND REFERRALS TO HOSPITAL ARE REDUCED FOLLOWING SACUBITRIL/VALSARTAN TREATMENT IN THE PRIMARY CARE AND CARDIOLOGIST SETTING IN GERMANYWachter, R. / Klebs, S. / Balas, B. / Kap, E.J. / Engelhard, J. / Schlienger, R. / Fonseca, A.F. / Proenca, C.C. / Bruce Wirta, S. et al. | 2018
-
PCP68 - MEDICAL ACCESS STRATEGY TO IMPROVE ACCESS TO INNOVATIVE AND EXPENSIVE THERAPY IN FRANCECohen, S. / Paubel, P. / Monchecourt, F. et al. | 2018
-
PCP69 - APPLICATION DECREE OF JARDE LAW: EXPERIENCE FROM A NON-INTERVENTIONAL STUDY IN FRANCEGuillemot, J. / Syed, I.A. / Jamet, N. et al. | 2018
-
PCP37 - THE CONFIDENTIALITY REGARDING DRUGS PRICING AND REIMBURSEMENT IN ROMANIAPaveliu, M.S. / Radu, P. et al. | 2018
-
PCN375 - ASSESSING NUTRITIONAL STATUS AMONG PATIENTS WITH LUNG CANCERPakai, A. / Istlstekker, I. / Vajda, R. / Csákvári, T. / Váradyné Horváth, Á. / Póhr, K. / Fusz, K. / Boncz, I. / Oláh, A. et al. | 2018
-
PCN359 - COMPARISON OF INSTITUTIONAL AND HOME HOSPICE CAREDeleróza, A. / Fusz, K. / Pusztai, D. / Csákvári, T. / Váradyné Horváth, Á. / Á, Müller / Boncz, I. / Oláh, A. et al. | 2018
-
PCN317 - THE CANCER DRUGS FUND: KEY UNCERTAINTIES, DATA COLLECTION PLANS, ANALYTICAL METHODS AND USE OF THE SYSTEMATIC ANTI-CANCER THERAPY (SACT) REAL WORLD DATA SETLatimer, N.R. et al. | 2018
-
PCN305 - NICE AND THE CANCER DRUGS FUND – CAN OBSERVATIONAL EVIDENCE INFORM FUNDING DECISIONS IN ONCOLOGY?Walsh, S. / Liu, L.W. / Macaulay, R. et al. | 2018
-
PCN289 - HOW ACCELARATED IS PATIENTS' ACCESS TO NEW ONCOLOGY PRODUCTS IN THE NEW ERA OF CANCER DRUG'S FUND IN ENGLAND?Bates, B.E. / Tsoumani, E. et al. | 2018
-
PCN332 - REAL-WORLD USAGE OF BORTEZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE (VTD) AS FRONTLINE (FL) TREATMENT IN STEM CELL TRANSPLANT (SCT) ELIGIBLE MULTIPLE MYELOMA (MM) PATIENTS ACROSS EU5 COUNTRIESAnjo, J. / Rider, A. / Bailey, A. / Gaudig, M. et al. | 2018
-
PCN287 - ANALYSIS OF IMPACTS OF THE SUPPLEMENTARY SCHEMES ON THE DRUG REIMBURSEMENT DECESION-MAKING UNDER THE POSITIVE LIST SYSTEM IN KOREAK.I.M., T. et al. | 2018
-
AC2 - USE OF MEDICINE PRICING AND REIMBURSEMENT POLICIES FOR UNIVERSAL HEALTH COVERAGE IN INDONESIAWasir, R. / Irawati, S. / Makady, A. / Postma, M.J. / Goettsch, W. / Feenstra, T. / Buskens, E. et al. | 2018
-
PCN339 - SPEAR-BLADDER (STUDY INFORMING TREATMENT PATHWAY DECISION IN BLADDER CANCER): TIMING OF TREATMENT FOLLOWING FIRST-LINE THERAPY IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC UROTHELIAL CANCER IN THE COMMUNITY ONCOLOGY SETTING IN THE UNITED STATESDoshi, G. / Bhanegaonkar, A. / Bharmal, M. / Phatak, H. / Boyd, M. / Aguilar, K.M. / Kearney, M. et al. | 2018
-
CV1 - A COST-EFFECTIVENESS ANALYSIS OF MULITI-GENE PHARMACOGENETIC TESTING IN ACUTE CORONARY SYNDROME PATIENTS FOLLOWING PERCUTANEOUS CORONARY INTERVENTIONDong, O. / Lee, C.R. / Wheeler, S.B. / Voora, D. / Dusetzina, S.B. / Wiltshire, T. et al. | 2018
-
AC1 - OUTCOME OF NEW DRUG NEGOTIATION PROCESS IN ITALY: APPROVAL CONDITIONS (2015-2018)Lidonnici, D. / Lanati, E.P. / Niedecker, S. / Isernia, M. / Ronco, V. et al. | 2018
-
CP2 - USING REAL WORLD DATA TO EXTRAPOLATE EVIDENCE FROM RANDOMIZED CLINICAL TRIALSWang, S.V. / Schneeweiss, S. / Gagne, J.J. / Evers, T. / Gerlinger, C. / Desai, R. / Najafzadeh, M. et al. | 2018
-
PHP366 - DEVELOPMENT OF THE UNIFIED SYSTEM OF ASSESSMENT OF LEVELS OF EVIDENCE AND GRADES OF RECOMMENDATIONS FOR THE RUSSIAN FEDERATIONKhachatryan, G.R. / Fedyaeva, V. / Omelyanovskiy, V. / Avxentyeva, M. / Sukhorukikh, O. / Galeeva, Z. / Lukyantseva, D. et al. | 2018
-
PCV159 - THE IMPACT OF SUBSEQUENT CARDIOVASCULAR (CV) EVENTS ON HEALTH RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH A PRIOR MYOCARDIAL INFARCTION (MI) - A SYSTEMATIC LITERATURE REVIEWGogna, S. / Cholasamudram, S. / Jindal, R. / Cristino, J. / Laires, P.A. et al. | 2018
-
PIN14 - BIOMEDICAL AND THERAPEUTIC PREDICTORS OF SURVIVAL TIME AND MORTALITY OF ADULT HIV/TB CO-INFECTIONS; A RETROSPECTIVE COHORT STUDYTadesse, N. / Fang, Y. et al. | 2018
-
PIN13 - THE INCIDENCE OF SURGICAL SITE INFECTION IN POLANDPrzekopinska, B. / Macioch, T. / Niewada, M. et al. | 2018
-
PIH38 - PREVALENCE OF PELVIC FLOOR DISORDERS AMONG WOMEN IN EASTERN REGION OF NEPALSubedi, L. / Regmi, M.C. et al. | 2018
-
PIH49 - KNOWLEDGE ABOUT MENSTRUAL HYGIENE – TOXIC SHOCK SYNDROMEKrizsics, V. / Váradyné Horváth, Á. / Oláh, A. / Csákvári, T. / Kozmann, K. / Boncz, I. / Radics, L. / Kis, T. / Pakai, A. et al. | 2018
-
PIH26 - PRACTICE TOWARD ANTIBIOTICS PREPARATION AMONG IRANIAN PARENTSPeiravian, F. / Sharif, Z. / Yousefi, N. / Alavian, Y. et al. | 2018
-
PHP357 - MAKING SENSE FROM ANTI-SENSE: LESSONS IN TRANSLATING EXPEDITED REGULATORY APPROVAL INTO REIMBURSEMENT AND COMMERCIAL SUCCESSBebee, T. / Macaulay, R. et al. | 2018
-
PIH15 - PREVALENCE OF DIAGNOSED UTERINE FIBROIDS AND ENDOMETRIOSIS IN THE US: DATA FROM A NATIONALLY REPRESENTATIVE POPULATION-BASED SURVEYCacheris, W.P. / Hunsche, E.G. et al. | 2018
-
PIH3 - CLINICAL AND DEMOGRAPHIC RISK FACTORS AND COSTS OF SURGICAL SITE INFECTION AFTER CAESAREAN SECTIONLeaper, D.J. / Holy, C.E. / Ghosh, E. / Chen, B.P. / Edmiston, C.E. et al. | 2018
-
PHP200 - A REVIEW OF ACHIEVEMENTS AND CHALLENGES OF IRAN'S HEALTH TRANSFORMATION PLANPeikanpour, M. / Esmaeli, S. / Yousefi, N. / Aryaeinezhad, A. / Rasekh, H.R. et al. | 2018
-
PHP147 - CHANGES IN THE NUMBER OF PHYSICIANS IN THE HEALTH CARE SYSTEM OF EUROPEAN COUNTRIESElmer, D. / Endrei, D. / Ágoston, I. / Horváth, L. / Molics, B. / Németh, N. / Horváthné Kívés, Z. / Boncz, I. et al. | 2018
-
PHP124 - INTRANSPARENT EXCEPTIONAL FUNDING IN FRANCE ENSURING CONTINUITY OF PATIENT ACCESS TO INNOVATIVE TREATMENTWeber, A. / Marre, C. / Leveque, D. / Toumi, M. et al. | 2018
-
PHP95 - THE STUDY OF DYNAMIC ADJUSTMENT MECHANISM OF MEDICAL SERVICE PRICE IN CHINALin, P. / Wang, Y. / Li, L. / Liu, B. et al. | 2018
-
PHP112 - DO PATIENTS KNOW ABOUT THEIR CHRONIC HEALTH PROBLEMS AND THE DRUGS THEY TAKE?Inoriza, J.M. / Cols, M. / Sanchez-Perez, I. / Ibern, P. / Coderch, J. / Carreras, M. et al. | 2018
-
PHP89 - CLASS CNN DRUGS IN ITALY: PURCHASE AND PRESCRIPTION BEHAVIOR IN ITALIAN HOSPITALSGallo, A. / Stanisic, S. / Neumann, U. / Berto, P. et al. | 2018
-
PHP84 - INVESTIGATING USAGE OF REFERENCE COUNTRIES FOR PRICING AND HEALTH TECHNOLOGY ASSESSMENT OF MEDICINES IN CEE COUNTRIESBenisheva Dimitrova, T. / Boncheva, E. / Cherneva, D. et al. | 2018
-
PHP94 - DOES THE ORPHAN DESIGNATION INCREASE THE CHANCES OF POSITIVE HTA OPINION IN FRANCE, GERMANY AND UK?Caban, A. / Tomassy, J. / Rémuzat, C. / Toumi, M. et al. | 2018
-
PHP68 - HOW REGULATORY PATHS FOR E-HEALTH SOLUTIONS COULD FURTHER IMPACT MARKET ACCESS IN THE UNITED STATES AND THE EUROPEAN UNIONKloc, K. / Lach, S. / Dusza, M. / Rémuzat, C. / Sediri, Y. / Palencia, R. / Abshagen, D. / Toumi, M. et al. | 2018
-
PHP64 - ALLOWABILITY OF OUTCOMES-BASED RISK-SHARING SCHEMES IN RUSSIA WITHIN CURRENT LEGISLATIVE HURDLESTolkushin, A. / Kokushkin, K. / Davydovskaya, M. / Ermolaeva, T. et al. | 2018
-
PHP45 - AN INITIAL ANALYSIS OF THE COST-BASED PRICING REVISIONS IN JAPANGillespie, E. / Campbell, P.R. / Halcovich, C. / Gaebler, J.A. et al. | 2018
-
PHP41 - IMPACT OF PRICE REGULATION ORDINANCE ON TOP 20 PRESCRIBED MEDICINES PRICES IN BOSNIA AND HERZEGOVINAČatić, T. / Jusufović, R. / Tabakovic, V. / Begovic, B. et al. | 2018
-
PHP27 - EFFECTIVENESS OF COMMUNITY-BASED INTERVENTIONS FOR THE PREVENTION AND TREATMENT OF MENTAL HEALTH PROBLEMS AND MENTAL DISORDERS IN THE GENERAL POPULATION: SYSTEMATIC REVIEWPerez, D.M. / Mejia, L.C. / Sánchez, M.R. / Garzón-Orjuela, N. / Eslava-Schmalbach, J. et al. | 2018
-
PHP22 - IS THE EUROPEAN BIOSIMILAR MEDICINES MARKET BECOMING UNSUSTAINABLE? AN EXPLORATION OF THE COMBINED IMPACT OF COMPETITION, INTERCHANGEABILITY, PROCUREMENT, AND PRICINGTeale, C.W. / Sogokon, P. / Panciera, D. et al. | 2018
-
PGI27 - THERAPEUTIC STRATEGIES UTILIZATION AND RESOURCES CONSUMPTION IN PATIENTS AFFECTED BY CROHN DISEASE (CD) OR ULCERATIVE COLITIS (UC) IN AN ITALIAN REAL-WORLD SETTING, VENETO REGIONPerrone, V. / Sangiorgi, D. / Alessandrini, D. / Polini, M. / Andretta, M. / Degli Esposti, L. et al. | 2018
-
PDB120 - EVALUATION OF HEALTH STATUS OF TYPE 2 DIABETES OUTPATIENTS RECEIVING CARE IN A TERTIARY HOSPITAL IN NIGERIAAdibe, M. et al. | 2018
-
PDB121 - QUALITY OF LIFE AND UTILITY VALUES FOR COST-EFFECTIVENESS MODELING IN JAPANESE PATIENTS WITH TYPE 2 DIABETESCrawford, B. / Ishii, H. / Takamura, H. / Nishioka, Y. / Langer, J. / Watanabe, M. / KIM, H.R. et al. | 2018
-
PDB124 - PERSONALIZED DIABETES MANAGEMENT: WHAT DO PATIENTS WITH DIABETES MELLITUS PREFER?Mühlbacher, A.C. / Juhnke, C. / Sadler, A. et al. | 2018
-
PHP314 - THE RISE OF NICE ADVICE ON THE USE OF PHARMACEUTICALS, MEDICAL DEVICES AND DIGITAL HEALTH CARE IN THE NHSStevenson, A. / Ling, C. / Unsworth, H. et al. | 2018
-
PHP301 - THE TIME IS NOW FOR EUROPEAN HTA: HOW WILL THE EVOLUTION OF EUROPEAN HTA IMPACT ACCESS TO INNOVATIVE MEDICINES?Laisné, E. / Allen, N. / Kolotourou, K. / Sattler-Ermacora, P. / Grosvenor, A. et al. | 2018
-
PHP289 - AN EXAMINATION OF DELAYS DURING NICE TECHNOLOGY APPRAISAL REVIEWSAmbrose, S. / Naci, H. / Chesters, C. / Osipenko, L. / Mossialos, E. et al. | 2018
-
PHP269 - DESIGN AND EVALUATION OF MALAYSIAN MODEL OF PHARMACEUTICAL PICTOGRAMSTumkur, A. / Kwan, S. / Chee, J. / Teoh, H. / Ingle, P. / Molugulu, N. et al. | 2018
-
PHP266 - MANAGED ACCESS PROGRAMS: A FIRST STEP FOR UK HTA?Pandolfo, R. / Britt, R. / Oxborough, R.P. et al. | 2018
-
PHP260 - A EUROPEAN ANALYSIS OF FIXED DOSE COMBINATIONS PRICE SETTINGVialard, L. / Beillat, M. / Niang, H. / Papadatos, A. et al. | 2018
-
PHP280 - IS THERE A REASON TO ARGUE FOR HIGHER DECISION-MAKING EFFICIENCY WITH SINATS?Ferreira, C. / Andreozzi, V. / Vandewalle, B. / Félix, J. / Félix, A.R. et al. | 2018
-
PHP263 - COST EFFECTIVENESS AND COST UTILITY ANALYSIS STUDIES OF FIXED DOSE COMBINATIONS – A STUDY BASED ON PUBMED DATABASEDharmagadda, S. / Bhat, B. / Udupa, N. et al. | 2018
-
PHP247 - RISK-BASED CONTRACTING AND U.S. INSURERS: PAYER WILLINGNESS TO PARTICIPATE AND PREFERRED METRICS IN CHRONIC INDICATIONSMoore, R. / Lewis, C. et al. | 2018
-
PHP239 - THE INTRODUCTION AND IMPLICATIONS OF THE COST-CONTAINMENT MEASURE 'THE SLUICE' FOR EXPENSIVE INNOVATIVE DRUGS IN THE NETHERLANDSTrip, A.M. / van Steen, C. / Hensen, M. et al. | 2018
-
PHP224 - TEMPORARY ACCESS STRUCTURES FOR INNOVATIVE, HIGH-VALUE THERAPIES: COMPARISON OF MODELS AND CONSEQUENT REIMBURSEMENT TIMELINESWeston, A. / El Ghannam, M. et al. | 2018
-
PDB57 - TRENDS IN USE OF DRUGS FOR DIABETES TREATMENT IN SLOVAKIA: REVIEW OF CONSUMPTION DATA FROM 2007 TILL 2017Didič, R. / Cmorej, P. / Babela, R. et al. | 2018
-
PDB54 - ESTIMATED EVENTS AVOIDED AND COST OFFSETS ASSOCIATED WITH USING CANAGLIFLOZIN TO TREAT PATIENTS WITH TYPE TWO DIABETES MELLITUS (T2DM) WITH OR AT HIGH RISK OF DEVELOPING CARDIOVASCULAR DISEASE (CVD) IN ENGLANDGarcia Sanchez, J.J. / Willis, M. / Nilsson, A. / Ericson, O. / Ball, P. / Dunlop, W. et al. | 2018
-
PDB39 - EMPAGLIFLOZIN FOR PATIENTS IN THE NETHERLANDS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE: A BUDGET IMPACT MODELVoorhaar, M. / Nurkanovic, L. / Ustyugova, A.V. / Dvortsin, E. / Postma, M.J. et al. | 2018
-
PDB10 - MACROVASCULAR AND MICROVASCULAR COMPLICATIONS OF TYPE 2 DIABETES MELLITUS AND ITS ASSOCIATED FREQUENCY OF HOSPITAL ADMISSIONKeni, R. / Dhalla, R. et al. | 2018
-
PDB4 - THE EFFECT OF STATINS USAGE ON DIABETIC EYE COMPLICATIONSHammad, M.A. / Syed Sulaiman, S.A. / Mohamed Noor, D.A. et al. | 2018
-
PDB34 - CHARACTERIZATION OF THE RISK OF DEVELOPING DIABETES MELLITUS THROUGH THE USE OF THE FINDRISC SCALE IN A VOLUNTARY INSURANCE IN COLOMBIARomero, M. / Romero, Y. / Molano, M. / Useche, L. et al. | 2018
-
PCV146 - SYSTEMATIC LITERATURE REVIEW OF UTILITY DECREMENTS ASSOCIATED WITH THE NON-FATAL MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)Jindal, R. / Natani, H. / Gogna, S. / Yenamandra, J. / Laires, P.A. / Cristino, J. et al. | 2018
-
PCV148 - A SYSTEMATIC LITERATURE REVIEW ON HEALTH STATE UTILITIES ASSOCIATED WITH NON-FATAL STROKELaires, P.A. / Natani, H. / Cholasamudram, S. / Gupta, S. / Jindal, R. / Cristino, J. et al. | 2018
-
PCV104 - BETA-BLOCKERS, ANGIOTENSIN II, AND ANGIOTENSIN-CONVERTING ENZYME INHIBITORS IN PATIENTS WITH HEART FAILURE. DIFFERENCES IN PRESCRIPTION BY GENDER, SOCIOECONOMIC STATUS AND COMORBIDITY AFTER A FIRST HOSPITALIZATION FOR HEART FAILUREGarmendia, I. / Millan, E. / Trujillo, T.G. / Aizpuru, F. / Librero, J. / Mateos, M. / Ogueta, M. / Etxagibel, A. / Apiñaniz, A. / Samper, R. et al. | 2018
-
PCV106 - EVALUATION OF PRICES AND SALES VOLUME OF CARDIO-VASCULAR MEDICINES IN COMMUNITY PHARMACIESKazaryan, I. / Sevikyan, A. et al. | 2018
-
PCN276 - MANAGED ACCESS AGREEMENTS UNDER THE CANCER DRUGS FUND (CDF): KEY METRICS AND DRIVERSAdler, B. / Privolnev, Y. et al. | 2018
-
PCN254 - TRENDS IN BRCA TESTING OVER TIME AND SOCIOECONOMIC DEPRIVATIONMartin, A. / Pedra, G.G. / Downing, J. / Collins, B. / Godman, B. / Alfirevic, A. / Pirmohamed, M. / Greenhalgh, K.L. et al. | 2018
-
PCN240 - ALL-COMERS VS. BIOMARKER BASED PATIENT SELECTION FOR BIOTHERAPIES IN ONCOLOGY: IMPACT ON DRUG DEVELOPMENT AND MARKET ACCESSMassetti, M. / Leleu, H. / Vimont, A. / Antier, C. / Blachier, M. et al. | 2018
-
PCN259 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH MELANOMA CANCER IN SPAINBarrull, C. / Á, Baltasar-Sanchez / Callejo-Velasco, D. / Gómez-Navarro, V. / Canal-Díaz, N. / Solozabal, M. et al. | 2018
-
PCN256 - INDICATION-SPECIFIC PRICING IN ONCOLOGY: HOW WILL U.S. PAYERS DETERMINE VALUE AMID THIS GROWING TREND?Moore, R. / Lewis, C. et al. | 2018
-
PCN246 - EVOLUTION OF ONCOLYTICS CONSUMPTION IN PORTUGAL OVER TEN YEARSRamos, C. / Moreira, A. / Furtado, C. / Alves da Costa, F. et al. | 2018
-
PCN181 - COST-UTILITY ANALYSIS OF ADJUVANT PERTUZUMAB-BASED REGIMEN IN WOMEN WITH HER2-POSITIVE BREAST CANCER IN ITALYPradelli, L. / Zaniolo, O. / Caputo, A. / Roussel, M. / Tournier, C. et al. | 2018
-
PCN211 - PATIENT CASE-MIX OF A TERTIARY CLINICAL CENTRE WITH PATIENTS DIAGNOSED WITH MALIGNANT MELANOMA BETWEEN 2012-2015Horváthné Kívés, Z. / Vajda, R. / Horváth, L. / Endrei, D. / Boncz, I. et al. | 2018
-
PCN184 - COST-EFFECTIVENESS OF NIVOLUMAB PLUS IPILIMUMAB IN ADVANCED MELANOMATibet, B. et al. | 2018
-
PCN168 - COST-EFFECTIVENESS OF SORAFENIB IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A SYSTEMATIC REVIEWTaheri, S. / Motevalli, M.H. / Peiravian, F. / Yousefi, N. et al. | 2018
-
PCN111 - COST ESTIMATE OF IMMUNE-RELATED ADVERSE REACTIONS ASSOCIATED WITH INNOVATIVE TREATMENTS OF METASTATIC MELANOMABini, C. / Mennini, F.S. / Marcellusi, A. / Del Vecchio, M. et al. | 2018
-
PCN110 - COSTS ASSOCIATED WITH TRACHEA, BRONCHUS AND LUNG CANCER IN RUSSIA IN 2016 YEARAvxentyeva, M.V. / Musina, N.Z. / Gorkavenko, F. / Nikitina, A. / Savilova, A.G. et al. | 2018
-
PCN90 - COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF NILOTINIB FOR THE SECOND LINE TRATMENT OF CHRONIC MIELOID LEUKEMIA IN THE RUSSIAN FEDERATIONAvxentyev, N.A. / Frolov, M.Y. / Makarov, A.S. et al. | 2018
-
PCN83 - THE USE OF OBINUTUZUMAB IN TREATMENT OF REFRACTORY AND RELAPSING FOLLICULAR LYMPHOMAKolbin, A. / Vilum, I. / Balykina, Y. / Proskurin, M. et al. | 2018
-
PCN393 - THE BURDEN OF INFORMAL CARE FOR BREAST CANCER PATIENTS IN THE NETHERLANDSGout-Zwart, J. / Vondeling, G.T. / Rozenbaum, M.H. / Beby, A.T. / Postma, M.J. et al. | 2018
-
PCN40 - A RETROSPECTIVE STUDY ON PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PRESCRIBED ABIRATERONE ACETATE + PREDNISONE PRIOR TO CHEMOTHERAPY IN SWEDEN, NORWAY AND DENMARKLeval, A. / Flordal Thelander, E. / Kjolhede, H. / Kongsted, P. / Lindberg, H. / Heinrich, D. / Andren, O. et al. | 2018
-
PCN86 - VALIDATION OF THE IMPACT OF TREATMENT EVOLUTION IN NON-SMALL CELL LUNG CANCER (NSCLC) MODEL (ITEN): A DISCRETE EVENT PATIENT SIMULATIONMoldaver, D. / Hurry, M. / Tran, D. / Grima, D. et al. | 2018
-
PCN25 - ROLE OF PROGRESSION FREE SURVIVAL IN THE APPROVAL PROCESS AND EUROPEAN HTA ASSESSMENTSKirchmann, T. / Deichmann, A. / Schönermark, M. et al. | 2018
-
PCN201 - IMPACT OF COMORBID DEPRESSION ON RATES, COSTS, AND HEALTH CARE RESOURCE USE IN LUNG CANCER PATIENTSMerritt, N. / Chung, J. / Kish, J. / Nabhan, C. / Feinberg, B.A. et al. | 2018
-
DS2 - EFFECTIVENESS AND SAFETY OF STANDARD AND REDUCED DOSES OF DABIGATRAN VERSUS RIVAROXABAN IN NON-VALVULAR ATRIAL FIBRILLATION: A COHORT STUDY IN THE SNDS FRENCH NATIONWIDE CLAIMS DATABASEBlin, P. / Cottin, Y. / Dureau-Pournin, C. / Abouelfath, A. / Lassalle, R. / Benichou, J. / de Pouvourville, G. / Mismetti, P. / Droz-Perroteau, C. / Moore, N. et al. | 2018
-
MO4 - COMPARING MIXTURE CURE MODELS WITH STANDARD PARAMETRIC MODELS WITHIN THREE- AND FIVE-STATE PARTITION SURVIVAL FRAMEWORKSvan Oostrum, I. / Buskens, E. / Ouwens, M.J. / Postma, M.J. / Heeg, B. et al. | 2018
-
CV4 - PATIENT AND CAREGIVER INDIRECT COSTS AFTER ACUTE CARDIOVASCULAR EVENTS IN EUROPESidelnikov, E. / Gerlier, L. / Kutikova, L. / Amarenco, P. / Kotseva, K. / Annemans, L. et al. | 2018
-
MD1 - EVIDENCE DEVELOPMENT TIMELINE OF MEDICAL DEVICES IN THE UK: WHERE DO MEDICAL INNOVATION BRIEFINGS FIT?Overhill, A. / Chen, G. / Upton, E. / Peirce, V.J. / Marsh, W. et al. | 2018
-
PCV54 - ESTIMATED ECONOMIC BURDEN OF ATRIAL FIBRILLATION IN GERMANY, ITALY, AND THE UKVelleca, M. / Patel, L. / Goyert, N. / Goldstein, L.J. / Costa, G. et al. | 2018
-
PCV41 - COST IMPACT ANALYSIS OF USING IMPROVE® TOOL FOR VENOUS THROMBOEMBOLISM RISK ASSESSMENT IN MEDICAL PATIENTS ADMITTED TO THE UK NHS HOSPITALS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATIONMather, I. / Dawoud, D. / Donald, I. / Chandra, D. / Sharpin, C. / Stansby, G. / Barry, P. et al. | 2018
-
PCV31 - ANTICOAGULANTS IN OLDER PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AFTER INTRACRANIAL HEMORRHAGEPerreault, S. / Côté, R. / Schnitzer, M. / White-Guay, B. / Oussaid, E. et al. | 2018
-
PCV30 - REAL WORLD EVIDENCE OF THE RISK OF STROKE OR SYSTEMIC EMBOLISM IN CHRONIC KIDNEY DISEASE PATIENTS WITH ATRIAL FIBRILLATIONKuranz, S. et al. | 2018
-
PCV10 - RANDOMISED CONTROLLED TRIALS IN HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF) – A SYSTEMATIC REVIEW (SR) OF INCLUDED PATIENT POPULATIONSAhuja, A. / Agrawal, R. / Thakur, L. / Natani, H. / Cristino, J. / Croft, D. / Gielen, V. et al. | 2018
-
PCP64 - DEVELOPMENT AND VALIDATION OF COGNITIVE PERFORMANCE-BASED OUTCOME (PERFO) ASSESSMENTSEdgar, C. et al. | 2018
-
PCP46 - A SIMPLE DECISION TREE TO IDENTIFY POTENTIAL APPLICATIONS OF MACHINE LEARNING AS AN ADDITION TO TRADITIONAL STATISTICAL ANALYSIS IN HEALTH ECONOMICS AND OUTCOMES RESEARCHCox, A. / Oguz, M. et al. | 2018
-
PCP21 - BIOSIMILARS IN THE UK – A 2018 UPDATEHendrich, J. et al. | 2018
-
PCP26 - THE EUNETHTA COMPANION GUIDE – A REPOSITORY TO STRENGTHEN THE QUALITY OF EUNETHTA'S JOINT HTA PRODUCTIONRehrmann, M. / Luhnen, M. / Fathollah-Nejad, R. / Nocon, M. / Hutner, H. et al. | 2018
-
PCN343 - KNOWLEDGE ABOUT HUMAN PAPILLOMAVIRUS (HPV) IN PARENTS OF TEENAGE BOYS IN HUNGARYSzóvári, Z. / Boncz, I. / Pakai, A. / Gyuró, M. / Endrei, D. / Csákvári, T. / Horváthné Kívés, Z. / Vajda, R. et al. | 2018
-
PCN346 - DISEASE SPECIFIC COST ANALYSIS OF THE NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER HEALTH STATESYanev, I. / Aprikian, A. / Nablsi, E. / Primiani, J. / Vaillancourt, Z. / Dragomir, A. et al. | 2018
-
PCN344 - NUTRITION BEHAVIOUR OF PATIENTS WITH BREAST CANCERKánya, K. / Vajda, R. / Horváth, L. / Boncz, I. / Endrei, D. / Horváthné Kívés, Z. et al. | 2018
-
PCN320 - RECOMMENDATIONS OF SPANISH THERAPEUTIC POSITIONING REPORTS FOR NEW ONCOLOGY DRUGS SINCE YEAR 2013Rebollo, P. / Ortega, T. et al. | 2018
-
PCN316 - RELATIONSHIP BETWEEN TWO CANCER CLINICAL BENEFIT FRAMEWORKS AND HEALTH TECHNOLOGY DECISIONS IN THREE EUROPEAN COUNTRIESBartsch, R. / Hashim, M. / Ouwens, D.M. / Postma, M.J. / Heeg, B. et al. | 2018
-
PCN308 - DO HEALTH TECHNOLOGY APPRAISALS HAVE AN IMPACT?: A COMPARISON OF CENTRALIZED AND REGIONAL APPROACHESCorbacho, B. / Drummond, M. / Santos, R. / Jones, E. / Borras, J. / Mestre-Ferrandiz, J. / Espín, J. / Henry, N. et al. | 2018
-
PCN277 - PREDICTORS OF HOSPITALIZATIONS AND EMERGENCY DEPARTMENT (ED) VISITS IN SECOND-LINE (2L) ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)Korytowsky, B. / Radtchenko, J. / Nwokeji, E. / Tuell, K. / Feinberg, B.A. et al. | 2018
-
PCN279 - A REVIEW OF RECOMMENDATIONS FOR INCLUSION AND DATA COLLECTION WITHIN THE CDF FRAMEWORKSabry-Grant, C. / Malottki, K. / Diamantopoulos, A. et al. | 2018
-
PCN358 - SATISFACTION WITH HEALTH CARE ANALYSIS IN CERVIX-UTERI CANCER MEXICAN WOMEN TREATED IN A THIRD LEVEL PUBLIC FACILITYGonzalez-Barba, F. / Balderas-Peña, L. / Sat-Muñoz, D. / Trujillo-Hernández, B. / Martinez-Herrera, B. / Alvarado-Zermeño, A. / Bayardo-López, L.H. / Salazar-Páramo, M. / López-Almaraz, L.M. / Hernández-Chávez, G.A. et al. | 2018
-
AD3 - EVALUATION OF THE "SOPHIA" ASTHMA PATIENT MANAGEMENT PROGRAM AT TWO YEARSGuillo, S. / De Rycke, Y. / Lafourcade, A. / Chenivesse, C. / Taillé, C. / Hejblum, G. / Tubach, F. et al. | 2018
-
CN3 - VALUE OF ADJUVANT ONCOLOGY THERAPIES: METHODOLOGICAL CHALLENGES OF MODELLING COST-EFFECTIVENESS OF AN ADJUVANT TREATMENT IN AN ERA OF HIGH-COST ONCOLOGY TREATMENTSKovacs, V. / Kiss, Z. / Tichy, E. / Benedict, A. et al. | 2018
-
PHP205 - BARRIERS TO AND FACILITATORS OF THE APPLICATION OF HEALTH TECHNOLOGY ASSESSMENT IN MEDICINE PRICING AND REIMBURSEMENT POLICIES IN INDONESIAWasir, R. / Irawati, S. / Makady, A. / Postma, M.J. / Goettsch, W. / Feenstra, T. / Buskens, E. et al. | 2018
-
PHP181 - HEALTH TECHNOLOGY ASSESSMENT OF ONCOLOGY THERAPIES IN SPAIN AND ITALY: KEY METRICS AND CONSIDERATIONSPrivolnev, Y. / Moore, R. / Sharma, K. et al. | 2018
-
PHP191 - EVALUATION OF THE RENEWED LIFE REFORM PROGRAM FOR WORKERS WITH PREMORBID METABOLIC SYNDROME, OVERWEIGHT AND OBESITY IN THE AMAZONAS ASSISTANCE NETWORK OF PERUVIAN SOCIAL SECURITYEspinoza, S. / Tafur, H. et al. | 2018
-
PHP180 - ACCESS AND VALUE OF HEALTHCARE INNOVATION IN LATIN AMERICAMartin de Bustamante, M. / Alfonso, R. / Boers Trilles, V. / Guarin, D.F. et al. | 2018
-
PHP173 - PHARMACEUTICAL PROCUREMENT IN UKRAINE: AN ANALYSIS OF NEW TRENDS IN IMPROVING ACCESS TO MEDICINESPiniazhko, O. / Zaliska, O. / Ilyk, R. et al. | 2018
-
PHP168 - TRUMP'S PLANS TO REDUCE DRUG PRICES: FROM THE CAMPAIGN TRAIL TO AMERICAN PATIENTS FIRSTDabbous, M. / Rémuzat, C. / Toumi, M. et al. | 2018
-
PHP175 - EVOLUTION OF THE HEALTHCARE EXPENDITURES BY SERVICES IN HUNGARY BETWEEN 2010 AND 2015Kovács, G. / Nogel, M. / Sebestyén, A. / Endrei, D. / Ágoston, I. / Csákvári, T. / Boncz, I. et al. | 2018
-
PHP157 - APETITE FOR ON PATENTS: COST OF PRESCRIBING SWITCHING IN GREECEManias, N.G. / Papadopoulos, K. / Stefanidou, Z. / Ollandezos, M. et al. | 2018
-
PHP140 - CURRENT CHALLENGES AND POTENTIAL SOLUTION FOR PRICING REGULATORY AND REIMBURSEMENT FRAMEWORK OF INNOVATIVE DRUGS IN EGYPTElMordy, B. / Fouad, S. / Elsisi, G.H. / Elmahdawy, M.D. et al. | 2018
-
PHP130 - SICK-PAY EXPENDITURES IN HUNGARY BETWEEN 2005-2016Kovács, G. / Nogel, M. / Sebestyén, A. / Endrei, D. / Csákvári, T. / Boncz, I. et al. | 2018
-
PHP135 - CHANGES IN THE NUMBER OF DENTISTS IN EUROPEAN COUNTRIES BETWEEN 2000-2015Elmer, D. / Endrei, D. / Ágoston, I. / Horváth, L. / Molics, B. / Németh, N. / Horváthné Kívés, Z. / Boncz, I. et al. | 2018
-
PHP120 - WHAT DO WE STAND TO LOSE? THE PROPORTION OF US-OWNED PHARMACEUTICALS ON AUSTRALIA'S PHARMACEUTICAL BENEFITS SCHEMEWeston, A. / Taylor, C. / Standfield, L. et al. | 2018
-
PHP115 - COMPARATIVE ANALYSIS OF THE MARKET PENETRATION OF PERSONALISED MEDICINE DRUGS UNDER THE CONDITIONS OF AMNOGFischer, T. / Bonduelle, D. / Antoni, B. et al. | 2018
-
PHP111 - EXPLORING THE LEVELS OF UNDERSTANDING OF PERSONALIZED MEDICINE AMONGST MEDICAL STUDENTS IN SARAJEVOHenic, H. / Music, E. / Mackic, M. / Hamzic, A. / Sofic, E. / Smailbegovic, E. / Čatić, T. / Jusufović, R. et al. | 2018
-
PHP87 - COULD THE FRENCH COHORT ATU PROGRAM BE THE MODEL EUROPE NEEDS TO HARMONIZE COMPASSIONATE USE PROGRAMS?Rivière, P. / Houzelot, D. / de Paz, B. / Salvignol, O. et al. | 2018
-
PHP74 - A REVIEW OF THE INFLUENCE OF INTERNATIONAL REFERENCE PRICING (IRP) ON LAUNCH SEQUENCING IN EUROPEMak, C. / Marshall, J.D. et al. | 2018
-
PHP33 - UNDERSTANDING THE JAPANESE POLICY INITIATIVES AND THE PATIENT CHARACTERISTICS OF RARE, INTRACTABLE DISEASESKIM, H.R. / Crawford, B. et al. | 2018
-
PGI45 - RELIABILITY AND VALIDITY OF A NEW PATIENT-REPORTED OUTCOME FOR GASTROPARESISCheng, R. / Barnes, C. / Zhou, K. / Morris, S. / Goyal, A. / Cole, J.C. et al. | 2018
-
PDB135 - THE BURDEN OF DIABETES MELLITUS IN TAIWAN BASED ON PATIENT-REPORTED OUTCOMESFang, H. / Chen, C. / Lin, H. / Tang, C. et al. | 2018
-
PDB123 - WHAT ARE THE MOST VALUED PATIENT OUTCOMES REGARDING MEDICAL CARE FOR FRENCH PATIENTS WITH TYPE 1 DIABETES? RESULTS FROM AN ONLINE PATIENT COMMUNITY (CARENITY.COM)Debroucker, F. / Delporte, L. / Ullmann, E. et al. | 2018
-
PHP347 - REGULATORY, POLICY AND OPERATIONAL BARRIERS TO OUTCOME-BASED RISK SHARING AGREEMENTS IN THE U.S. MARKET: OPPORTUNITIES FOR REFORMGoodman, C. / Villarivera, C. / Gregor, K.J. / van Bavel, J. et al. | 2018
-
PHP334 - PHYSICIAN-RELATED FACTORS IN DOCTOR-SHOPPING: A SYSTEMATIC LITERATURE REVIEWJaafer, N. / Biernikiewicz, M. / Toumi, M. et al. | 2018
-
PHP264 - QUALITATIVE ANALYSIS OF CLINICAL TRIALS RELATED TO DIABETES REGISTERED WITH CLINICAL TRIAL REGISTRY OF INDIABhat, B. / Dharmagadda, S. / Udupa, N. et al. | 2018
-
PHP241 - INSIGHTS FROM PREVIOUS ATMP ASSESSMENTS IN THE UNITED KINGDOM, GERMANY AND FRANCE FOR FUTURE CAR-T REVIEWSSchuurman, S.M. / Poeton, A.K. / Delaitre-Bonnin, C. et al. | 2018
-
PHP245 - UNDERSTANDING THE IMPACT OF REAL WORLD EVIDENCE ON REIMBURSEMENT DECISIONS ACROSS EU5 COUNTRIES USING A WEB-BASED PORTAL TO ENGAGE PAYERSKumar Singh, K. / Clapton, G.S. / Rebelo de Sousa, C. / Tripathi, S. et al. | 2018
-
PHP236 - QUALITY OF EVIDENCE ON THE COST-EFFECTIVENESS OF DRUGS PROPOSED FOR THE INCLUSION IN THE RUSSIAN VITAL AND ESSENTIAL DRUGS LIST IN 2014-2017Bezdenezhnykh, T. / Omelyanovskiy, V. / Avxentyeva, M. / Sura, M. et al. | 2018
-
PDB61 - COST-EFFECTIVENESS ANALYSIS OF HUMAN OR ANALOGUE BASAL INSULIN-SUPPORTED ORAL THERAPY IN TYPE 2 DIABETES IN HUNGARYNémeth, T. / Tabák, Á / Bán, A. / Bacskai, M. / Tarcsa, M. et al. | 2018
-
PDB23 - THE CLINICAL GAP BETWEEN THE GUIDELINES AND PRACTICE OF STATINS PRESCRIBING AMONG DIABETIC PATIENTSHammad, M.A. / Syed Sulaiman, S.A. / Aziz, N.A. / Mohamed Noor, D.A. et al. | 2018
-
PDB21 - COMPARATIVE EFFECTIVENESS OF SGLT2 INHIBITORS IN TYPE II DIABETES DERIVED FROM AN OVERVIEW OF 55 SYSTEMATIC REVIEWSOrigasa, H. / Yotsutani, N. et al. | 2018
-
PDB51 - RESULTS OF THE COSMODIA STUDY: ESTIMATING THE IMPACT ON THE NUMBER OF CLINICAL COMPLICATIONS AND THE ASSOCIATED POTENTIAL FINANCIAL BENEFIT AS A CONSEQUENCE OF BETTER MANAGEMENT OF GLYCAEMIC CONTROL IN PEOPLE WITH TYPE 2 DIABETES IN SPAINMata-Cases, M. / Mahon, J. / Mauricio, D. / Franch-Nadal, J. / Real, J. / Hex, N. et al. | 2018
-
PDB63 - COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN TREATMENT IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC HEART FAILURE BASED ON SUBGROUP OF EMPA-REG OUTCOME IN THE UNITED KINGDOMReifsnider, O. / Kansal, A. / Franke, J. / Lee, J. / George, J.T. / Brueckmann, M. / Kaspers, S. / Brand, S. / Ustyugova, A. / Linden, S. et al. | 2018
-
PDB28 - TYPE 2 DIABETES: CHANGING PATTERNS OF USE OF THE VARIOUS CLASSES OF ANTIDIABETIC DRUGS 8 YEARS AFTER STARTING TREATMENT: A NATIONWIDE COHORT STUDY USING THE FRENCH NATIONAL HEALTH DATA SYSTEM (SNDS)Aguade, A. / Gastaldi-Menager, C. / Karsenty, D. / Baudot, F. / Fontaine, P. / Fagot-Campagna, A. et al. | 2018
-
PDB1 - ACUTE RENAL OUTCOMES WITH SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS- REAL WORLD DATA ANALYSISMelzer Cohen, C. / Cahn, A. / Pollack, R. / Shalev, V. / Chodick, G. et al. | 2018
-
PCV141 - MEDICATION ADHERENCE AND POTENTIAL DETERMINANTS FOR NON-ADHERENCE IN YOUNG AND MALE PATIENTS AT CVD RISK IN KOREAChae, I. / Cha, J. / Kim, Y. et al. | 2018
-
PCV152 - TREATMENT BURDEN ASSOCIATED WITH DIFFERENT ANTICOAGULATION STRATEGIES OF ATRIAL FIBRILLATION PATIENTS: AN OBSERVATIONAL STUDY IN GERMANY, SWEDEN AND SWITZERLAND BASED ON THE ANTI-CLOT TREATMENT SCALEWilke, T. / Bloempott, S. / Henry, M. / Mueller, S. et al. | 2018
-
PCV110 - TREATMENT WITH FREE TRIPLE COMBINATION THERAPY OF ATORVASTATIN, PERINDOPRIL, AMLODIPINE AND ATORVASTATIN IN PATIENTS WITH HYPERTENSION: A REAL-WORLD POPULATION STUDY IN ITALY.Perrone, V. / Veronesi, C. / Degli Esposti, L. et al. | 2018
-
PCN267 - HEALTHCARE UTILIZATION AND ECONOMIC BURDEN ON PATIENTS WITH BLADDER CANCER IN THE US DEPARTMENT OF DEFENSE POPULATIONXie, L. / Sun, X. / Mallampati, R. / Wang, Y. / Yuce, H. / Baser, O. et al. | 2018
-
PCN206 - ANAPLASTIC LYMPHOMA KINASE (ALK) TESTING IN NON-SMALL CELL LUNG CARCINOMA (NSCLC): RECOMMENDED TESTS AND COVERAGE POLICIES ACROSS ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT (OECD) COUNTRIESKumar, J. / Patel, R. / Aggarwal, P. / Adler, B.N. / Gupta, J. et al. | 2018
-
PCN194 - COST-EFFECTIVENESS OF SCALING-UP CERVICAL CANCER SCREENING RATES AND HPV VACCINE INITIATION IN TURKEYSozmen, M.K. / K.O.C., E.M. / Kaplan, Y.C. et al. | 2018
-
PCN183 - ROBOTIC VERSUS LAPAROSCOPIC SURGERY FOR RECTAL CANCER: A COMPARATIVE STUDY OF CLINICAL OUTCOMES AND COSTS-EFFECTIVENESSNuñez Alfonsel, J. / Ielpo, B. / Quijano, Y. / Vicente, E. / Hidalgo, A. et al. | 2018
-
PCN195 - COST-UTILITY ANALYSIS OF THE GERMLINE BRCA TESTING IN WOMEN WITH EPITHELIAL OVARIAN CANCER WITHOUT FAMILY HISTORY IN SPAINGonzález-Domínguez, A. / Moya, C. / Simón, S. / Jiménez-Torres, M. / Bayo-Lozano, E. / Sánchez-Heras, A. / González-Martín, A. et al. | 2018
-
PCN145 - COST-EFFECTIVENESS OF NINTEDANIB FOR THE TREATMENT OF NON-SMALL LUNG CANCER IN PORTUGALAlmeida, J. / Tavares, A. / Vandewalle, B. / Félix, J. / Andreozzi, V. / Viana, D.S. et al. | 2018
-
PCN197 - COST UTILITY ANALYSIS OF FIRST-LINE PACLITAXEL WITH CARBOPLATIN AND BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB VERSUS PEMETREXED WITH CARBOPLATIN FOLLOWED BY MAINTENANCE PEMETREXED IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER IN LEBANONTfayli, A. / Elias, F. / Farhat, F. / Slim, R. / Hallal, Z. / Maatouk, L. / Ibrahim, A. / Anan, I. et al. | 2018
-
PCN146 - INOTUZUMAB OZOGAMICIN IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE LYMPHOCYTIC LEUKEMIA (ALL): ESTABLISHING A VALUE-BASED COST – PRELIMINARY RESULTSChen, Z. / Xiao, H. / Diaby, V. et al. | 2018
-
PCN123 - EVALUATION OF DRUG THERAPY COSTS FOR PATIENTS WITH BREAST CANCER, MELANOMA AND RENAL CELL CARCINOMA IN MOSCOW IN 2016-2017Krysanova, V. / Poliakova, K. / Ermolaeva, T. / Davydovskaya, M. / Kokushkin, K. et al. | 2018
-
PCN151 - COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB IN THE TREATMENT OF PATIENTS WITH HEPATOCELULLAR CARCINOMA PREVIOUSLY TREATED WITH SORAFENIB IN PORTUGALAndré, S. / Graça, A. / Soares, V. et al. | 2018
-
PCN98 - PALLIATIVE TREATMENT AND ITS COST IN THE LAST SIX MONTHS OF LIFE FOR METASTATIC COLORECTAL CANCER PATIENTSMerth, G. / Á, Rumszauer / Mokrai, D. / Ruzsa, V. / Füleki, G. / Halmai, L. / Rózsa, P. et al. | 2018
-
PCN95 - A MULTICENTRIC EVALUATION OF CONSUMABLES AND TRANSPORTS COST OF BREAST CANCER PATIENT'S TREATED BY TRASTUZUMAB ACCORDING TO THE ADMINISTRATION FORM (IV VERSUS SC)Blein, C. / bernard Marty, C. / Priou, V. / Borg, M.C. / mouret-Reynier, m / Lebozec, G. / Tournamille, J. / Jaffre, A. / PEREZ staub, N. / Alfonsi, R. et al. | 2018
-
PCN106 - ECONOMIC BURDEN OF END-OF-LIFE AGGRESSION IN LUNG CANCER PATIENTS FROM THE FRENCH HEALTH INSURER PERSPECTIVEBylicki, O. / Blein, C. / Tournier, C. / Canoui-Poitrine, F. / Chouaid, C. et al. | 2018
-
PCN94 - COST-EFFECTIVENESS OF CABOZANTINIB VERSUS SUNITINIB OR PAZOPANIB AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE UKSkentzou, E. / Meng, J. / Lister, J. / Gray, L. et al. | 2018
-
PCN52 - PREVALENCE AND INCIDENCE OF DIFFERENT TYPES OF CANCER IN GERMANY: AN EPIDEMIOLOGICAL ANALYSIS BASED ON CLAIMS DATA OF MORE THAN 2.9 MILLION INSURED PERSONSLee, S. / Heidler, T. / Mueller, S. / Wilke, T. / Maywald, U. et al. | 2018
-
PCN7 - A TIME WITHOUT SYMPTOMS OR TOXICITY ANALYSIS OF NIRAPARIB COMPARED WITH ROUTINE SURVEILLANCE IN THE MAINTENANCE TREATMENT OF PATIENTS WITH RECURRENT OVARIAN CANCERMirza, M.R. / Walder, L. / Monk, B.J. / Tinker, A.V. / Mahner, S. / Gil-Martin, M. / Kalbacher, E. / Waters, J. / Wenham, R.M. / Malander, S. et al. | 2018
-
MD4 - DIGITAL HEALTHCARE EVALUATION AT NICE: AN EVOLVING PROCESSUnsworth, H. / Stevenson, A. et al. | 2018
-
PCN139 - COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER WHO ARE INELIGIBLE FOR CISPLATIN-CONTAINING CHEMOTHERAPY IN ENGLANDTsoumani, E. / Dillon, R.J. / Zhong, Y. / Prabhu, V.S. / Xu, R. / Li, H. et al. | 2018
-
PCV58 - HEALTH INSURANCE TREATMENT COST OF SECONDARY HYPERTENSION IN HUNGARY: A NATIONWIDE COST OF ILLNESS STUDYGazsó, T. / Boncz, I. / Sebestyén, A. / Zemplényi, A. / Gratz, B. / Endrei, D. et al. | 2018
-
PCV51 - COST ANALYSIS OF SAFETY OUTCOMES OF DABIGATRAN VS. WARFARIN IN THE SPANISH NATIONAL HEALTH SERVICESolé, A. / Male, N. / Manganelli, A. / Serra-Burriel, M. et al. | 2018
-
PCV9 - VENOUS THROMBOEMBOLISM PROPHYLAXIS STRATEGIES FOR PEOPLE UNDERGOING ELECTIVE TOTAL KNEE REPLACEMENT: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATIONLewis, S. / Glen, J. / Dawoud, D. / Dias, S. / Cobb, J. / Griffin, X. / Rossiter, N. / Reed, M. / Sharpin, C. / Stansby, G. et al. | 2018